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Part I. A new route for the preparation of azetidin-2-ones was studied
using a tandem photochemical deprotection and ring contraction of pyrazolidin-
3-ones as the key step. Pyrazolidin-3-ones 112-116 were first protected at the
N-1 position with o-nitrobenzyl chloride yielding derivatives 117-121 which were
acylated with 2-(trimethylsilyl)ethyl azidoformate to give the fully protected
pyrazolidinones 125, 126, 131, 132, and 134 needed for photolysis. Irradiation
of these compounds through a Pyrex filter removed the o-nitrobenzyl group,
and subsequent photolysis using a Vycor filter effected ring contraction to afford
N-(acylamino)azetidinones 137, 138, 141, 142, and 144. These were converted
to N -am inoazetidinones 1 61-1 6 5 with tetra-n-butylammonium fluoride.
Completion of a general entry to the parent 0-lactams 183-1 8 8 was
accomplished by a nitrosative deamination with N,N-diphenylnitrosamine.
Synthesis of the known precursor 220 to the antibiotic PS-5 (10) was
achieved using this methodology in ten steps from 8-valerolactone (208) and in
an overall yield of 1.3%. Treatment of a,p-unsaturated-S-lactone 211, prepared
from 208 in three steps, with hydrazine monohydrate furnished pyrazolidinone
Redacted for Privacy2 1 2.Confirmation of the cis configuration was obtained by X-ray
crystallographic analysis of the o-nitrobenzyl derivative 215. Photolysis of the
fully protected pyrazolidinone 217 gave N-(acylamino)azetidinone 218 in good
yield. Removal of both silyl protecting groups in 218, followed by nitrosative
deamination of 219, produced 220.
Part II. Synthesis of the C20-C34 subunit 73 of the immunosuppressant
drug FK-506 (1) was accomplished in fifteen steps in an overall yield of 2.8%.
(-)-Quinic acid (66) was used as the starting material and was first converted to
the bicyclic bromoimidazolide 79. Simultaneous reduction of the alkyl bromide
and imidazolide moietiesin 79 with tri-n-butyltin hydride and a,a'-
azobisisobutyronitrile gave 68 in good yield. Acid-catalyzed opening of lactone
68 with methanol, followed by formation of the methyl ether, provided ester 69
which was homologated to a,0-unsaturated aldehyde 75 in five steps.
Condensation of 75 with the chiral enol borinate 88 afforded alcohols 89 and 90
in a 2.4:1 ratio, respectively. Conversion of the desired alcohol 89 to aldehyde
74 was accomplished by silylation and selective oxidative cleavage of the
terminal olefin in 91.Completion of the synthesis of 73 was achieved by
stereoselective aldol condensation of the lithium enolate of ketone 100 with
aldehyde 74.Part I:Synthesis of Azetidin-2-ones from Pyrazolidin-3-ones.
Part II: Synthesis of a Subunit of the Immunosuppressant FK-506.
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I-A. Introduction
Sir Alexander Fleming's discovery in 19291 that penicillin was an
effective antibiotic against different bacterial cultures started the era of research
into penicillin antibiotics.It was not until 1940, when Florey found that penicillin
F (1) could protect mice from otherwise fatal injections of bacteria, that penicillin
was thought to have medicinal value. This started an intense research effort
that eventually led, through the use of Penicillium notatum, to large scale
production of penicillin G (2). The latter was used as an effective antibiotic for
the treatment of infections in injured World War II soldiers.
H
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With the subsequent evolution of penicillinase-producing bacteria, in
which the enzyme inhibits penicillin activity, the utility of penicillin G became
limited. This unfortunate phenomenon motivated researchers to find alternative
penicillin derivatives for medical use.
The structure of penicillin was studied intensively after 1943. This led to
the extraordinary suggestion by Robinson that penicillin contained a 13-lactam
ring.2 Later, in 1945, it was confirmed by X-ray crystallographic analysis that
penicillin did indeed contain the 13-lactam nucleus.3
In the 1950's, two important discoveries contributed to the advancement
of research on 0-lactam antibiotics. The first, in 1953, was the isolation of2
cephalosporin C (3) by Abraham from Cephalosporium acremonium.4 This
compound showed significant activity against Gram-positive and Gram-negative
bacteria. Although 3 was hydrolyzed by the penicillinase enzyme it showed
greater resistance to penicillinase-producing bacteria than penicillin G.
CO2H
OAc
3
The second event, probably the most important development in this field,
was the isolation of useful quantities of both 6-aminopenicillanic acid (4) from
Penicillium chrysogenium,5 and 7-aminocephalosporanic acid (5) by chemical
removal of the side chain of 3.6
OAc
This led to the semisynthesis of large numbers of penicillins and
cephalosporins which were evaluated for biological activity. Four of the most
effective antibiotics synthesized commercially are illustrated below.Methicillin
NH2
nN,N
N . OAc 0
CO2H
Cephalothin
0
CO2H
Ampicillin
CO2H
Cefazolin
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In the 1970's, as new screening procedures were developed, several
new classes of f3-lactam antibiotics emerged which were found to have
therapeutic value.7 These included 13-lactamase inhibitors of E. Co li and
Penicillium aeruginosa foundinStreptomyces microorganisms such as
clavulanic acid (6)8 and the monocyclic 13-lactam norcardicin A (7)9.
O
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6
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During this period and subsequently into the 1980's the carbapenem
family and its relatives were discovered. Nearly forty different compounds were
isolated from several different Streptomyces strains. Members of this family
which showed powerful biological activity include thienamycin mu), PS -54
(10)11, PS -6 (11)12,olivanic acid (12)13,and carpetimycin A (13).14
Interestingly, there were several epi-thienamycin structures reported such as
915; however, epi-compounds related to PS-5 (10), PS-6 (11), olivanic acid
(12), and carpetimycin A (13) have yet to be isolated.
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Concurrent with the emergence of the carbapenems was the discovery
of the monobactams. These are monocyclic f3-lactams containing a sulfonic
acid moiety on the ring nitrogen. Sulfazecin (14), isolated from Pseudomonas
acidophfia in 1981,16 is an example of a monobactam. This compound is active
against strains of Gram-negative bacteria, including Pseudomonas aeruginosa
and Escherica Coll. Analogues of sulfazecin such as 15 were also isolated and
tested for biological activity.It was found that the monobactams with methoxy5
substitution at C-3 of the azetidinone ring, as in 14, were the most resistant to
p-lactamase-producing bacteria.17
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Although the synthesis of a fl-lactam was accomplished by Staudinger as
early as 1907,18 it was not until the late 1950's, when interest in these
compounds was increasing rapidly, that the first (3-lactam antibiotic was
synthesized.In 1959, Sheehan published a total synthesis of optically pure
penicillin V (16).19
16
(D)-Penicillamine (17), a degradation product of the penicillins, was
condensed with phthalimidomalonaldehyde 18 to afford, among other products,
the thiazolidine 19.After replacement of the phthalimido group with the
phenoxymethyl side chain to yield 20, hydrolysis of the t-butyl ester set the
stage for ring closure. This was accomplished by treatment of the amino acid
21withoneequivalentofpotassiumhydroxidefollowedby
dicyclohexylcarbodiimide, and provided the desired penicillin V potassium salt
22 in 10% yield (Scheme 1).The efficiency of this cyclization was later
improved to 25% using diisopropylcarbodiimide.20HS
H2N
17 O
18
CHO
CO21 -Bu
AcONa, H2O
(30%)
t-BuO2C
19CO2H
1. NH2NH2;
aq. HCI, (82%)
2. PhOCH2COCI
Et3N, (79%)
6
PhOCH2CONH PhOCH2CONH
)---r 1. HCI, CH2%,(91%)_ S\/
HO2C HN ..* t-BuO2C HN-....r.
2. Pyridine, (81%)
21CO2H 20b02H
1. KOH, (1 eq.)
2. DCC, dioxane,
H2O, NaOH, (10%)
Scheme 1
In 1966, Woodward and co-workers completed an impressive total
synthesis of cephalosporin C (3).21 The starting material, (L)-cysteine (23), was
converted to thiazolidine derivative 24 in three steps.Reaction of 24 with
excess diethyl azodicarboxylate (DEAD) in the presence of lead tetraacetate
resulted in stereospecific hydroxylation to give 25. The hydroxyl group of 25
was then converted to the amino function of 26 with inversion of configuration.
Cyclization of 26 was effected with triisobutylaluminum to yield the bicyclic 13-
lactam 27. A further eight steps were needed for completion of this route to 3.
Unlike the Sheehan synthesis,19 where the Prlactam ring was closed late in the
synthesis, Woodward's construction of the p-lactam unit occured relatively early7
in the sequence, a strategy which enabled intermediate 27 to be used for both
penicillin and cephalosphorin syntheses (Scheme 2).22
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There are many other syntheses of penicillins in the literature which form
a body of work in the area of classical p-lactam antibiotics.23 However, with the
discovery of new structural classes of p-lactam antibiotics in the 1970's the
synthetic chemist was forced to develop new strategies for their synthesis.
In 1978, Wasserman reported the synthesis of (±)-3-aminonocardicinic
acid (28)24, an attractive intermediate previously used in the synthesis of
norcardicin A (7).25 This synthesis illustrated a novel ring expansion which led
to the 3- lactam nucleus. Addition of the aminomalonate 29 to cyclopropanone
30 gave alkylaminocyclopropanol 31 in quantitative yield. Compound 31 was
chlorinated to form the chloramine 32 which underwent ring expansion to form
33 in 40% yield, accompanied by chloroamide 34 in 30% yield. Chloroamide 34
was cyclized to the desired p-lactam 33 in good yield. The p-lactam 33 was8
advanced to the 3-azido deriviative 35 using lithium diisopropylamide and p-
toluenesulfonyl azide. A further four steps were needed for the preparation of
racemic 28.
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During the same period, Bentley and co-workers reported a synthesis of
the oxapenem antibiotic (±)-clavulanic acid (6) (Scheme 4)26.Alkylation of9
racemic 4-methylthioazetidin-2-one (36)27 with methyl-y-bromoacetate (37)
provided the enolized13-keto ester 38 in low yield. This substance was treated
with a small excess of chlorine in carbon tetrachloride to give 39 which was
taken directly to the bicyclic oxapenem 40 without purification. Azetidinone 40,
which has the unnatural stereochemistry of the exocyclic double bond, was
obtained as the sole stereoisomer.Isomerization of the double bond was
accomplished by irradiation of 40 in benzene which gave 40 and 41 in a 3:2
ratio,respectively.Reduction of the mixture of 4 0 and 41with
diisobutylaluminum hydride afforded a separable mixture of racemic methyl
clavulanate 42 and racemic methyl isoclavulanate 43 in low yield.
CO2Me ,SMe
(2 eq.) NaH,
DMF, (29%)
37
CO2Me
CO2Me
40
hv, benzene
3:2 (40/41)
K2CO3,
DMF, (34%)
CO2Me
DIBAL-H,
Toluene, -78°C
CO2Me
41
Scheme 4
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The synthesis of carbapenem-based antibiotics encompasses a large
volume of work due to the many different structural variations that have been
encountered.28 The strategies which have been developed generally take into
account the different C-6 alkyl side chains and the C-3 cysteaminyl side chains.
The majority of these syntheses have employed construction of the 13-lactam
nucleus before elaboration to the [3.2.0]bicylic framework.These ring
constructionstrategiesincludechiralamino acidcyclizations,2 9
chlorosulfonylisocyanate-alkene cycloadditions,32,33 acid chloride-imine
cycloadditions,34and ester enolate-imine cyclizations.36
One of the most elegant approaches using a chiral amino acid cyclization
for construction of the 13-lactam ring is found in the synthesis of (+)-thienamycin
(8) by Salzmann and co-workers at Merck.29 The synthesis started from
dibenzyl aspartate (44), available from (L)-aspartic acid.30 The amino ester 44
was monosilylated and cyclized to azetidinone 45 upon treatment with tert-
butylmagnesium chloride. After several more steps, this route culminated in the
construction of 8 via a rhodium (II) acetate catalyzed carbenoid cyclization of
diazoketone 46 to give the carbapenem nucleus of 47.29,31 The latter was then
converted to 8 by straight forward means (Scheme 5).The carbenoid
cyclization was a pivotal achievement and has been used in many formal
syntheses of carbapenem antibiotics.32,33,34,35jC 02Bn
1. TMSCI
BnO2C NH2
HO
44
2. t-BuMgCI,
(70%)
Rh(I1)acetate
.44
80°C, benzene
47 CO2PN Bquantitative
8
1. CIP0(013h)2, DMAP,CH3C N
2.
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An example of theutilityof a chlorosulfonylisocyanate (CSI)
cycloaddition to an alkene was published by Favara in his synthesis of 6-epi-
PS-5 (48)32 and (+)-PS-5 (10).33 A [2+2] cycloaddition using excess CSI with
conjugated diene 49, followed by reductive hydrolysis, yielded a four-isomer
mixture of 13-lactams 50 in moderate yield (Scheme 6).32 The cis isomer 51,
separated by crystallization from diisopropyl ether, was converted to the
corresponding acid 52 in two steps. Completion of the synthesis of 48 was
achieved using the method developed at Merck.29,31'R'
CISN=C=0
0
1--ttu.., (CSI);
OAc
Na2SO3,
49 Na2HPO4,
NaOH, (50%)
H
1-.1 CO2H1) H2, 10%Pd/C
NH 2) Me0H, K2CO3;
0 KMnO4, pH7 buffer
52
48
CO2H
NHAc
Scheme 6
OAc
crystallization
H H OAc
NH
0
51
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The synthesis of (+)-PS-5 was accomplished using the mixture of
isomers 50 without purification (Scheme 7).33 Catalytic hydrogenation of 50,
followed by methanolysis provided alcohol 53. Simultaneous protection of the
alcohol and lactam yielded acetonide 54, which was epimerized with 1N
potassium tert-amylate to afford the trans isomer 55. Removal of the protecting
group gave the trans alcohol which was oxidized to the corresponding acid 56
with potassium permanganate. Optical resolution of 56 using Chirald furnished
57 which was converted to (+)-PS-5 again using the Merck methodology.29,31OAc
NH
50
1. H2, 10%Pd/C, (100%)
2. K2CO3, Me0H, (85%)
55
r
O
NH
53
2,2-dimethoxypropane
H H
potassium tent-amylate---.
1N 0,
1. 10% AcOH
(65% from 53)
2. KMnO4, (60%)
Hti
C 02H
" NH
0
(±)-56
Me
(Chirald)
Scheme 7
N(Me)20
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H1:1
NH
(+)-57
OH
C 02H
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Shinkai and co-workers reported the use of an acyl chloride-imine
cycloaddition in their synthesis of (+)-thienamycin (8).34 Acid chloride 58 was
treated with diisopropylethylamine to generate ketene 59, which underwent
[2+2]-cycloaddition with imine 60 to afford 13-lactams 61 and 62 in a 7:1 ratio
respectively (Scheme 8).Desilylation of 61 resulted in epimerization at C-4
forming the desired trans-p-lactam 63.Inversion of stereochemistry at the
hydroxylethyl side chain utilizing the Mitsunobu protocol,35 followed by removal14
of the p- methoxyphenyl (PMP) group, provided 0-lactam 64 which was
converted to the known thienamycin intermediate 46 in two steps.
OTIPS
C OC I
58
i-Pr2EtN
OTI PS
H
I
0
59
0
Ph)
NPMP
60
(90%)
TIPS() FR? TIPSO
= H 2*-1 Efl COPh
n-BuiNF,THF
...(
1?11.PMP
(78%)
63 61 (7:1) 62
COPh
PMP
+
E 14
v COPh
0 PMP
1. DEAD, Ph3P,HCO2H
2. CAN (67% two steps)
HO) COPh
NH
0
64
1. MCPBA
2. ZnBr2,
N2
yLCO2PNB
OTMS
46
Scheme 8
Preparation of the p-lactam nucleus using the enolate-imine approach
was first reported by Cainelli.36 Tert-butyl butanoate 65 was treated with lithium
bis(trimethylsilyl)amide, followed by silylimine 66, yielding a 96:4 mixture of 13-
lactams 67 and 68, respectively (Scheme 9).After deprotection of 67, the15
resulting alcohol was oxidized with chromic acid to ketone 69 which was then
converted to acetate 70 by Baeyer-Villiger oxidation.13-Lactam 70 was
converted via diazoketone 71 to 10.29,31
65
C 02t-Bu
LiN(SiMe3)2, THF,
-78°C, (61%);
OTBDMS 0
-\1.4 YOAc
0,
NH
70
NSi(Me)3
66
MCPBA, (72%)
..(
OTBDMS OTBDMS
H 1:1 H H
NH +
NH
67
1
0
68
1. HF, MeCN, (97%)
2. H2CrO4, Et20, (72%)
Hti
,-NH
0
69
N2
CO2PNB, ZnBr2,(68 %)
OTMS
H H
eNH 0
71
CO2PNB
Scheme 9
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The syntheses of monobactams closely parallel the synthetic routes
illustrated in the construction of carbapenem antibiotics.The strategies
employed include chiral amino acid cyclizations, [2+2]-cycloadditions, and
enolate-imine condensations.3716
Foremost among the syntheses involving a chiral amino acid cyclization
are those developed by Miller.38Hydroxamate 72 was closed to N-
benzyloxyazetidinone 73 using two different methods (Scheme 10). Sequential
reductive debenzylation and N-0 bond cleavage with titanium (Ill) chloride gave
the desired 0-lactam 74.
HOH BOCN BOG N
DEAD,Ph3P or
PhCH20,
H
72
Ph3P, CC14, Et3N
H
BOCN
Scheme 10
OCH2Ph
73
1. H2, 10%Pd/C
2. TIC13
NH
74
Important new methodology for constructing the monobactam nucleus by
means of a transition metal-mediated cycloaddition was reported by
Hegedus.39 This approach is similar to previously reported [2+2J-cycloadditions
of an imine with a photogenerated ketene intermediate.0-Lactam 77 was
produced cleanly and in good yield upon irradiation of the chromium carbene
complex 75 in the presence of imine 76 (eq. 1).
N(Bn)2HH hv, MeCN
(Bn)2N
(CO)5Cr + 11
H tL
t-Bu
(72%) 0 t-Bu
75 76 77
(1)17
The synthesis of N-amino-O-lactams as potential precursors of
monobactam analogues was examined by Curran.40 He found that N-Boc-
protected (L)-serine 78 could be coupled to hydrazone 79 to afford hydrazide 80
(Scheme 11).Cyclization of 80 was accomplished using Mitsunobu
conditions 35 to yield 0-lactam 81. Hydrogenation of 81 gave N-amino-f3-lactam
82 needed for production of N-azamonobactam analogues.
(OH
N OEt
Ph
1
CO2Et
BOCNACO2H+ NH2N .BOCN
H Ph (EEDQ) H
78 79 (64%)
OH
H Ph
1 N
Ph
0
80
DEAD, Ph3P
(66%)
H H BOCN BOCN
H2, Pd/C
Ph
..,:(
Ph
'NH2
82
Scheme 11
81
N-Aza-13-lactam 83 was synthesized from 82 and was found to have
good biological activity against Gram-negative bacteria.41
H2N
N-0Me
H
N
0
83
Me
,1.....,-(
C 02H18
Many studies of photochemical ring contractions as routes to 13-lactams
have been reported.42All except one have involved five-membered ring
contractions to the 13-lactam nucleus. Several of these are outlined below.
Lowe has described the synthesis of 13-lactams using a photolytic Wolff
rearrangement.43 He found that 3-diazo-5-methylpyrrolidine-2,4-dione (84)
underwent a ring contraction which gave a 8:5 mixture of 13-lactams 85 and 86,
respectively, in excellent yield (eq. 2).
Me BOCHNHN BOCHNHN
hv, Pyrex vessel
NH 0 + benzene, 0°C,
0 BOCNHNH2, (90%) 0
NH
0
NH
84 85 86
(2)
Stork also used the Wolff rearrangement to prepare bicyclic f3-lactams.44
Diazotetramic acid 87 was photolyzed in good yield and gave a 2:5 mixture of
easily separated (3-lactams 88 and 89, respectively.Compound 88 was
epimerized to 89 with great ease, thus leaving the ratio of initially formed
products open to question (eq. 3).
0 H
O
87
hv, Pyrex filterMe02C
Me0H, 0°C,
(65%)
H H
Me02C
88 89
(3)
Nagata found that 4-pyrimidones undergo photolytic ring contraction
forming 13-lactam products.45 For example, pyrimidone 90 was irradiated in
methanol to give the corresponding azetidinone 93 in 58% yield.It was
suggested that bicyclic intermediate 91 and 13-lactam 92 were involved in the
formation of 93 (Scheme 12).Me Me
M e,,
N N hv, Me0H,
ii....
Me,N
quartz filter 0)
3.5h, 30°C,
90 (58%) 91
Me,Me
N OMe
0\
NH2
93
Scheme 12
NI(
Me
Me,Me
N OMe
92
NH
19
Padwa devised a new approach to the 13-lactam nucleus, in which he
found that isoxazolidines, formed from nitrone cycloadditions, contract when
subjected to irradiation.46Isoxazolidine 94 was subjected to ultraviolet
irradiation and produced only the trans-P-lactam 95 (eq. 4).
t-Bu, CN ,Ph
hv
,"NO2 s ,N,
0 't -Bu
CN
93 94
(4)
Among the known photolytic ring contractions which lead to a p-lactam,
one reported by Ege,47 in which the pyrazolidin-3-one 95 was shown to afford
N-aminoazetidinone 96 upon irradiation, seemed especially well suited for
further development (eq. 5).R
R
N
NHhv, Me0H 1:1
0,' N Vycor filter 0 \NHPh Ph (20%)
95 96
This reaction was further investigated by Johnson,48 who found that the
overall efficiency of the reaction was increased when an electron-withdrawing
group was present at N2 of the pyrazolidinone ring (eq. 6). Pyrazolidinones 97
were photolyzed to the N-acylazetidinones 98 in a wide range of yields
dependent on the R group.
(5)
20
hv, Me0H
Vycor filter
(65-20%)
98
(6)
In order for acylation at N2 to be accomplished, it was necessary to
protect the more nucleophilic N1 nitrogen of the pyrazolidinone ring. This was
carried out using an interesting rearrangement reaction (Schemel3).48 The
protected pyrazolidinone 100 was prepared from 99 using 2,2,2-
trichloroethoxycarbonyl (TROC) chloride. Reaction of 100 with benzoyl chloride
and triethylamine gave exclusively 101 which, upon treatment with zinc in acetic
acid, yielded 102. The latter underwent rearrangement as shown in 103 to 104,
the desired precursor for ring contraction.It was also found that
pyrazolidinones such as 101 undergo thermal rearrangement to produce the
desired N-acyl products like 105 in good yield (eq. 7).----\( TROCCI, .---
NH NTROC
0
N 2N NaOH,,,-Ni
(52%) ki H
99
104
0
103
+ PhCO2H
100
PhCOCI, THE
Scheme 13
N TROCA, 110°C
3h, (60%)
101
Et3N, (70%)
0 Ph
101
21
NTROC
Zn, AcOH,
(60%)
105
102
(7)22
The foregoing work demonstrates that a photochemical ring contraction
of pyrazolidin-3-ones offers a feasible route to N-substituted 13-lactams.
However, there are several limitations to this approach, including the difficulty of
selective acylation at N2 to obtain the starting materials, the low yield of the ring
contraction, the necessity for removing an N-amino function from the product
azetidinone, and, finally, the lack of functional group variability needed to
complete a useful 13-lactam synthesis.23
I-B. Results and Discussion
The objectives of this work were to develop an efficient synthesis of 13
lactams using the photochemical ring contraction of pyrazolidin-3-ones
discovered by Ege and to extend this methodology toward applications aimed at
producing useful intermediates for carbapenem or monobactam antibiotics.
Attempts to improve the Ege-Johnson methodology in the hope of
producing new N-substituted 13lactams was first undertaken in these
laboratories by Slater.49He showed that the pyrazolidin-3-one starting
materials could be readily prepared by condensation of hydrazine monohydrate
with either an a4 unsaturated ester or the corresponding acid. For example,
ester 106 was converted to pyrazolidinone 99 using hydrazine monohydrate in
refluxing ethanol in good yield (eq.8).
CO2 Et
106
NH2NH2'H20
2NH
EtOH, A, (78%)0 HN
99
(8)
Unfortunately, selective acylation at N2 of these pyrazolidinones, to
provide the precursor for ring contraction, necessitated a lengthy protection-
acylation-deprotection sequence as outlined below (Schemel4). Protection of
99 as either the TROC derviative 107 or the carbobenzyloxy (Cbz) analogue
108 was followed by acylation to their corresponding N-tert-butoxycarbonyl
(BOC) pyrazolidinones 109 and 110 which, upon deprotection, afforded 111.99
CICO2CH2CC13
NaOH, THF
(57%)
CICO2CH2Ph,
NaOH, THF,
(48%)
(t- BuOCO)20
0 NCbz DMAP, Et3N: 0
H CH2Cl2, (91%)
108
107
(t- BuOCO)20
TROC
DMAP, Et3N, 0
CH2Cl2, (75%)
110
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An attractive alternative to this cumbersome procedure involved the use
of a photolabile protecting group at N1 which would enable the ring contraction
to be carried out in tandem with deprotection. The o-nitrobenzyl protecting
group50 appeared to meet the specifications of a photolabile group which would
not interfere with azetidinone formation, and Perri found that N1-substituted
derivatives 117-121 were easily prepared from their corresponding
pyrazolidinone precursors 112-1 1 6witho-nitrobenzyl chloride and
dimethylformamide in the presence of sodium iodide and triethylamine
(Table1) .4925
NH
o-nitrobenzyl chloride,
DMF, Nal, Et3N, r.t.
H
Starting
materials
Ri R2 Productsyield, (%)
112 Me H 117 63
113 H Me 118 56
114 Me Me 119 71
115 H H 120 65
116 H CH2CO2Et 121 32
Table 1. Preparation of 1-(o-Nitrobenzyl) pyrazolidin-3-ones.
Several different acyl groups were used in combination with 117-121 to
effect activation at N1 (Table 2). Acetyl derivatives 122 and 128 were obtained
using Johnson's procedure outlined previously. Benzyl and ethyl carbamates
124 and 127 were prepared from their corresponding chloroformate esters.
The BOC derivatives 123, 129, 130 and 133 were synthesized using tert-
butoxycarbonic anhydride in the presence of 4-(dimethylamino)pyridine
(DMAP).51[2-(Trimethylsilyl)ethoxy] carbonyl (TEOC) derivatives 125, 126,
131, 132, and 134 were prepared by the method of Carpino using2-
(trimethylsilyl)ethyl azidoformate.5226
Starting
Materials
R1 R2 R3 Productsyield (%)
117 Me H Me 122 77
117 Me H O -t -C4H9 123 98
117 Me H OCH2C6H5 124 73
117 Me H OCH2CH2SiMe3125 73
118 H Me OCH2CH2SiMe3 126 81
118 H Me OEt 127 73
118 H Me Me 128 82
118 H Me O -t -C4H9 129 96
119 Me Me O -t -C4H9 130 99
119 Me Me OCH2CH2SiMe3 131 59
120 H H OCH2CH2SiMe3132 90
121 HCH2CO2Et 0-t-C4H9 133 94
121 HCH2CO2EtOCH2CH2SiMe3134 90
Table 2. Preparation of 1-(o-NitrobenzyI)-2-acylpyrazolidin-3-ones.
Irradiation of pyrazoldinones 123-134 was carried out with a 450-W
medium pressure Hanovia lamp using a Pyrex filter for 1h and then a Vycor
filter for 2h producing azetidinones 135-144 (Table 3).27
hv, EtOH
1. Pyrex, 1h
2. Vycor, 2h
Starting
Materials
R1 R2 R3 Productsyield, (%)
123 Me H 0- t-C.4H9 135 84
124 Me H OCH2C6H5 136 17
125 Me H OCH2CH2SiMe3 137 60
126 H Me OCH2CH2SiMe3 138 44
129 H Me 0-t-C4H9 139 65
130 Me Me 0- t-C4H9 140 79
131 Me Me OCH2CH2SiMe3 141 55
132 H H OCH2CH2SiMe3 142 34
133 HCH2CO2Et O -t -C4H9 143 58
134 H CH2CO2EtOCH2CH2SiMe3 144 41
Table 3. Tandem Photochemical Conversion of Pyrazolidin-3-ones to 1-
(Acylamino)azetidin-2-ones.
The BOC derivatives 135, 139, 140, and 143 were generally isolated in
the best yields from (58%-84%), while the TEOC derivatives 137, 138, 141,
142, and 144 were isolated in yields varying from 34% to 60%. The one
reaction leading to a Cbz-substituted azetidinone derivative (136) gave only a
17% yield.
A mechanism which accounts for the sequence of steps that leads from
(1- o-nitrobenzy1)-2-acylbyrazolidin-3-one 145 to N-(acylam ino)azetid in-2-one
153 is shown in Scheme 15.R'
;.1..\11
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0
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The initial excitation of 145 with a Pyrex filter occurs at wavelengths >
300 nm50 causing the o-nitrobenzyl substituent to undergo a Norrish type II
rearrangement to 146. A facile electrocyclic cyclization of 146 generates 147
which fragments to give the N1-unsubstituted pyrazolidinone 148 and o-
nitrosobenzaldehyde 149.53 Irradiation of pyrazolidinone 148 at a wavelength >
210 nm through a Vycor filter results in formation of a radical anion-radical
cation species 150 via an intramolecular electron transfer from the excited state
of 148. Bond closure of 150 leads to the bicyclic intermediate 15148 which then
undergoes bond reorganization to 152. The latter yields 153 following proton
transfer from 152.
The possibility of an alternative mechanism for the ring contraction was
proposed and examined by Ege54 and Johnson.48 A Norrish type Iring
opening of pyrazolidinone 154 to intermediate 155 was considered. This would
be followed by intramolecular hydrogen atom abstraction to give ketene 156
which would then cyclize to azetidin-2-one 157 (Scheme 16).
11NH hv, Norrish I
N!'
R'
154
R' = phenyl or acyl
rli
fr-N
0 sNR'
157
.14
Scheme 16
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155
O; ,NH
HN
Fit
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Johnson ruled out this mechanism by performing the photolysis of 105 in
deuteriated methanol.48If the ketene mechanism was operative, then 158
should show incorporation of a deuterium atom at the 3-position of the 13lactam
ring (eq. 9). Mass spectral analysis of the product revealed no incorporation of
deuterium in the product from 105.
hv, Me0D NH 0 (9)
0Me
105 158
Ege also showed that the ring contraction cannot be occurring through a
ketene intermediate in the photolysis of 159 to give 160 (eq. 10). X-ray crystal
structures of both the starting material and product proved that the reaction
proceeded with complete retention of configuration, a result which would not
have been expected if a ketene were involved.84
HO HO
H
NH
Ph
159
hv
NPh
H
160
(10)
A practical route to N-aminoazetidinones was found through cleavage of
the TEOC derivatives.49 Azetidinones 137, 138, 141, 142, and 144,when
treated with tetra-n-butylammonium fluoride in acetonitrile, afforded the desired
N-aminoazetidinones 161-165 in good yield (Table 4).31
R2
0 N, _IL
il0Ns.Si(M03
nBu4NF, CH3CN
50°C
Compound R1 R2 Products Yield, (`)/0)
137 Me H 161 73
138 H Me 162 58
141 Me Me 163 73
142 H H 164 88
144 H CH2CO2Et 165 33
Table 4. Preparation of 1-Aminoazetidin-2-ones.
The BOC derivatives 139, 140, and 143 were eliminated as N-
aminoazetidinone precursors when attempts to remove the BOC group with
trifluoroacetic acid resulted in clean rearrangement of the azetidinone to the
pyrazolidinone nucleus.49,55 The Cbz derivative 136 was hydrogenated to
afford N-aminoazetidinone 161 in good yield (eq. 11); however, the use of Cbz
derivatives was made impractical by their low isolated yield in the photolysis
step.32
This tandem photochemical ring contraction was extended to include a 13-
lactam bearing the hydroxyethyl side chain characteristic of thienamycin.
Treatment of hydroxy ester 16656 with hydrazine monohydrate gave the known
pyrazolidinones 167 and 16857 as a 1:1 mixture of diastereomers which were
readily separated by silica gel column chromatography (Scheme 17).
Stereochemical assignments were made on the basis of the Ha-Hb coupling
constants.The more polar isomer 167 (Jab = 2.5 Hz) was assigned the
thienamycin relative stereochemistry based on the empirical rule that Jab
(erythro) < Jab (threo).58The Ha-Hb proton pair of diastereoisomer 168
exhibited a larger coupling constant (Jab = 8.9 Hz) and was therefore assigned
the threo configuration. Treatment of 167 with o-nitrobenzyl chloride afforded
the expected N1-alkylated pyrazolidinone which, without purification, was
converted directly to its tert-butyldimethylsilyl ether 169. Acylation at N2 was
accomplished using 2-(trimethylsilyl)ethyl azidoformate and yielded
pyrazolidinone 170. Photolysis of 170 through Pyrex and then through Vycor
produced azetidinone 171 in good yield. Selective deprotection of 171 by brief
contact with one equivalent of tetra-n-butylammonium fluoride afforded 172 in
60% yield.Further deprotection of 172 with one equivalent of tetra-n-
butylammonium fluoride provided the desired N-amino alcohol 173 in 34% yield.OH
1)rCO2CH3
TBDMSO
166
N'
H2NNH2.H20,
Me0H
A, 4h
(76%)
0
NO2
SiMe3
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Cleavage of the N-N bond in N-(acylamino)azetidinones is a necessary
transformation for a general entry into the N-unsubstituted 13-lactam system.
This transformation was initially investigated by Perri who showed that N-
acetylamino derivatives such as 174 were inert to hydrogenolysis with Raney
nickel. He also found that they underwent decomposition with electron transfer
reducing agents such as samarium diiodide.59Perri demonstrated that
nitrosation of 174 proceeded in good yield to give nitrosohydrazide 175 which
was converted to the N-acyloxyazetidinone 177 together with 174 in basic
refluxing chloroform (Scheme 18). The formation of 177 can be explained by
an intramolecular N-0 acyl rearrangement followed by extrusion of nitrogen
from diazo ester 176, a documented deamination process.6°
0 NaNO2, AcOH,
Ac20, (77%)
H
174
0
OAMe
177
-N2
Scheme 18
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Perri further examined this deamination protocol using N-BOC
derivatives.He showed that urethane 178 could be nitrosated with either
sodium nitrite and acetic acid or with dinitrogen tetroxide gas to give 179
(Scheme 19).Unfortunately,179 failed to undergo acyl transfer to 180 in
analogy to 175. The principal outcome was denitrosation to 178.
NIO-t-Bu
H
178
Me
NaNO2, AcOH,
Ac20, (69%) or
N204, NaOAc,
CHCI3, (36%)
Scheme 19
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179
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iii
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The difficulty of removing the nitrogen substituent from the N-
acylazetidinones prompted the search for an alternative approach. Although it
appeared attractive at first glance, adaption of Miller's conditions for reductive
cleavage of N-hydroxy rilactams,38 using an acidic solution of titanium (Ill)
chloride, had to be ruled out since N-aminoazetidinones undergo ring
expansion to pyrazolidinones under acidic conditions.
Ganem showed that simple trifluoroacetamides undergo smooth
nitrosation and rearrangement to deaminated products,61 and an extension of
this procedure to our more complex 0lactam system was next investigated.
Treatment of N-aminoazetidinone 172 with trifluoroacetic anhydride (TFAA)36
produced the N-trifluoroacetylaminoazetidinone 181 in good yield.However,
nitrosation of 181 under Ganem's conditions failed to produce the desired
rearrangement product 182 and resulted only in decomposition (Scheme 20).
Attempts to nitrosate 181 with nitrogen tetroxide were also unsuccessful.
TBDMSO
0 'NH2
172
TBDMSO
TFAA, DMAP,
Pyridine, 0°C
(55%) 0NICF3
181
NaNO 2, AcOH,
Ac20, 0°C
Scheme 20
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A solution to the problem of removing the N-amino substituent from the
azetidinones was finally found in a report by Rees and Storr.62 They showed
that deamination of a 1-aminotriazine could be accomplished with
diphenylnitrosamine.63 When N-aminoazetidinones 161-165 were exposed to
this reagent, 0lactams 183-188 were obtained in good yield (Table 5).59 The
azetidinone 188 has been used as an intermediate in the synthesis of several
carbapenem antibiotics, including PS-5, PS-6, and thienamycin.64R1 R2
N
0 NH2
Ph
N NO
Phi
A,3h, benzene
37
Compound R1 R2 Product Yield ( %)
161 Me H 183 55
162 H Me 184 51
163a Me Me 185,186 67
164 H H 187 61
165 H CH2CO2Et 188 65
a cis: trans mixture (3.5:1) of 185 and 186 was obtained and separated by chromatography.
Table 5. Nitrosative Deamination of 1-Aminoazetidin-2-ones.
The aminoazetidinone 172 was deaminated to give 189 in good yield.
The latter was deprotected with hydrofluoric acid in acetonitrile to afford 190, a
13lactam possessing the thienamycin side-chain configurations (Scheme 21).
TBDMSO
AFLI
0 NH2
172
Ph
NNO
Phi
TBDMSO
A,3h, benzene,
(68%)
Scheme 21
189
HO
5% HF,
MeCN, (64%)
19038
A probable mechanism for this deamination involves transnitrosation of
191 to yield 192 and diphenylamine. The diazotate tautomer 193 would
undergo elimination of N20 to give the parent 13lactam 194 (Scheme 22).
Ph2NNO
Ph2NH
R
ci=1NN,
N'0 NsN
0 N- %0H
192 193
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With a complete route to N-unsubstituted 13-lactams completed, our
interest next turned to extending this methodology to the synthesis of more
complex carbapenem antibiotics. Our target was the known intermediate 19529
which could be accessed via azetidinones 196 and 197. Construction of the
bicyclic pyrazolidinone precursor 198 was envisioned by stereoselective
conjugate addition of hydrazine-monohydrate to a,I3unsaturated 8lactone 199
followed by cyclization.Lactone 199 would be available from ethyl (3 R)-
hydroxybutyrate 200. (Scheme 23).HO
H 1:1
CO2H
0
195
> H
NH 0 0/\Si(CH3)3
O
39
196 197
200
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The dianion of ethyl (3R)-hydroxybutyrate 200 was alkylated with allyl
bromide producing 20165 which was protected as its silyl ether 202 using
standard conditions.66 Hydroboration-oxidation67 of 202 with disiamylborane
proceeded smoothly to alcohol 203 (Scheme 24).OH
CO2Et
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Hydroxy ester 203 was oxidized to the corresponding carboxylic acid 204
with pyridinium dichromate.68Deprotection of 204 with hydrofluoric acid
resulted in an approximately 1:1 mixture of lactone 205 and the corresponding
acyclic hydroxy acid. The crude mixture was converted entirely to 205 using
Mukaiyama's lactonization conditions.69The enolate of lactone 205 was
treated with diphenyldisulfide to give the a-sulfenyl lactone 206 which, on
oxidation with m eta-chloroperbenzoic acid, produced an intermediate
sulfoxide.70 Without purification, the sulfoxide was exposed to refluxing toluene
causing elimination and isomerization of the resultant olefin to lactone 199.
Several attempts to form the desired bicyclic pyrazolidinone 198 from 199 were
unsuccessful, the addition of hydrazine-monohydrate to 199 generally giving
rise to polymeric products (Scheme 25).TBDMSO
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A rationale for the failure to form 199 was apparent by comparison to the
results of Saito and co-workers.71 They found that treatment of lactone 199
with phenylhydrazine produced pyrazolidinone 206 in 65% yield (Scheme 26).
This shows that the terminal nitrogen of phenyihydrazine reacts selectively at42
the lactone carbonyl and is followed by cyclization.Pyrazolidinone 206 was
converted to lactone 207, a known intermediate in route to thienamycin.72
0 EtoA
0)L NH2NH2Ph,
H--
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EtOH, 40°C, (65%) 'Ph
CO2Et H
199 206
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207
Scheme 26
Attempts to reduce the lactone carbonyl of 199 with diisobutylaluminum
hydride in toluene at -70°C produced the corresponding lactol in a disappointing
25% yield.Allternatively, acidic or basic hydrolysis of 199 in an attempt to
obtain the a,13-unsaturated carboxylic acid resulted in elimination to diene
products.
The unfavorable reactivity of lactone 199 led to a reevaluation of our
strategy as an approach to 13-lactam antibiotics.An alternative plan was
developed which led eventually to the formal synthesis of PS-5 (10).73 This
strategy was based on the earlier observation that a,(3 unsaturated &-lactones
undergo hydrazinolysis to form pyrazolidinones via intramolecular cyclization at
the lactone carbonyl.43
This approach to the required a,(3 unsaturated 8lactone 211 with the
ethyl side-chain necessary for constructing PS-5 utilized 8valerolactone (208)
as a starting material. The lithium anion of 208 was akylated with ethyl iodide to
afford 209.74 Selenation75 gave 210 which upon oxidation followed by
elimination provided exclusively the endocyclic a,13unsaturated lactone 211.
Treatment of 211 with hydrazine monohydrate in refluxing ethanol gave the
desired cis-3,4-dialkylpyrazolidinone 212, accompanied by saturated hydrazide
213 and unsaturated hydrazide 214 in a 5:3:1 ratio, respectively (Scheme 27).
0
O LDA, HMPA, -70°C
208
H
EtI, 18h, (65%)
OH
NH
0 H
212 (50%)
209
OH
0 NHNH2
213 (30%)
OH
0 NHNH2
214 (10%)
LiN(SiMe3)2,THF,
-70°C, PhSeCI, 1h,1flSePh
(72%)
Scheme 27
30% H202, CH2Cl2,
0°C to r.t., 20 min.,
(91%)
NH2NH2 H2O
EtOH, A, 52h,
210
21144
To rationalize this result, it was proposed that the reaction of 211 with
hydrazine leads initially to cis and trans addition products 215 and 216 (Scheme
28).Only 216 is capable of undergoing transformation to the bicyclic
intermediate 217 leading to pyrazolidinone 212 which, as a result, possesses
cis configuration.
211
OH
215
214
OH
213
OH
Scheme 28
216
217
Apparently, 214 does not undergo cyclization using these reaction
conditions since its exposure to refluxing ethanol for 24 hours failed to produce45
any cis or trans pyrazolidinone.Instead 214 is reduced in low yield with
hydrazine to the saturated hydrazide 213.
The structure of 212 was determined by o-nitrobenzylation which
provided the monobenzylated pyrazolidinone 215 in modest yield (eq. 12).
Confirmation of cis stereochemistry of this substance was obtained by X-ray
crystallographic analysis (Figure 1).76
H
NH
0 H
212
OH
o-nitrobenzyl bromide
DMF, Et3N, 96h, 25°C,
(40%)
Figure 1. X-ray Crystal Structure of Pyrazolidinone 215.46
Continuation of the route from 215 required protection of the primary
alcohol,andthiswaseffectedwitht e r t-butyldimethylsilyl
trifluoromethanesulfonate to give 21 6.N2-Acylation of 216 with 2-
(trimethylsilyl)ethyl azidoformate produced the fully activated pyrazolidinone
217 needed for photolysis. Irradiation of 217 in ethanol, first through Pyrex and
then through a Vycor filter, resulted in smooth conversion to cis azetidinone 218
(Scheme 29).
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Treatment of 218 with two equivalents of tetra-n-butylammonium fluoride
resulted in removal of both silyl protecting groups to give 219 in good yield47
(Scheme 30). Nitrosative deamination of 219 finally gave the desired 0lactam
220, a known intermediate in the synthesis of (+)-PS-5.33 The Ha-Hb coupling
constant in 220 (Jab = 5.4 Hz) compared well with that of cis-substituted 13
lactams reported by Miller.77
218
n-Bu4NF (2 eq.),
MeCN, r.t., 15h,
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0 NH2
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It is evident from these results that this ring contraction methodology can
provide entry to useful carbapenem intermediates. The opportunity to create
hybrid structures,such as fllactam 190, or analogues, such as 220 containing
the unnatural cis stereochemistry, is a particularly valuable asset of this
chemistry.48
I-C. Experimental
General
Starting materials and reagents purchased from commercial suppliers
were generally used without further purification.Solvents were dried by
distillation from the appropriate drying agent immediately prior to use.
Toluene, tetrahydrofuran, and ether were distilled from potassium and
benzophenone under an argon atmosphere. Diisopropylamine, triethylamine,
diisopropylethylamine, dimethylformamide,acetonitrile,pyridine and
dichloromethane were distilled from calcium hydride under argon.All
solvents used for routine isolation of products and chromatography were
reagent grade and glass distilled.Moisture and air sensitive reactions were
carried out under an atmosphere of argon.
Concentration in vacuo refers to the use of a rotary evaporator at water
aspirator pressures.Residual solvent was removed by vacuum pump at
pressures less than 2 torr. Reaction flasks were flame dried under a stream of
argon. Syringes were oven dried at 200°C and cooled to room temperature in
a desiccator over anhydrous calcium sulfate.
Analytical thin layer chromatography (TLC) was conducted using 1.5 x
5.0 cm precoated aluminum E. Merck TLC plates (0.2 mm layer ,thickness of
silica gel 60 F-254). Spots were visualized by ultraviolet light, or by heating
the plate after dipping in a 3-5% solution of phosphomolybdic acid in ethanol,
10% ammonium molybdate, or a 1% solution of vanillin in 0.1M H2SO4 in
methanol. Flash chromatography was carried out using E. Merck silica gel 60
(230-400 mesh ASTM).49
Melting points were measured using a Buchi melting point apparatus.
Optical rotations were measured on a Perkin-Elmer 243 polarimeter at
ambient temperature using a 1 decimeter cell of 1 mL capacity. Infared (IR)
spectra were recorded with a Nicolet 5DXB FT-IR spectrometer. Proton and
carbon nuclear magnetic resonance (NMR) spectra were obtained using
either a Bruker AC-300, or Bruker AM-400 spectrometer.All chemical shifts
are reported in parts per million (ppm) downfield from tetramethylsilane using
the S scale. 1H NMR spectral data are reported in the order of: chemical shift,
multiplicity, (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and b
= broad), coupling constant (J) in Hertz, and number of protons. Mass spectra
MS(CI) were obtained using the Finnigan 4023 quadrapole GC-MS
spectrometer with a 4500 source at 140°C and a vacuum of 0.7 torr. Mass
spectra MS(EI) were obtained using the varian MAT311 with an ionization
potential of 70 eV.High resolution mass spectra were obtained using the
Kratos MS-50 RF spectrometer.X-ray crystallographic data was collected
using the Rigaku AFC6R instrument. Elemental analyses were performed by
Desert Analytics, Tucson, Arizona.
4-[(11-Hydroxy)ethyl]pyrazolidin-3-one (167). To a solution of
16656 (825 mg, 6.42 mmol) in 15 mL of absolute methanol was added
hydrazine hydrate (0.34 mL, 1.06 mmol) using a syringe.The resulting
solution was heated at reflux for 4 h then concentrated in vacuo to a viscous
oil.Purification by column chromatography on silica gel with 15% methanol-
chloroform as the elutant provided (634 mg, 76%) of a 1:1 mixture of
diastereomeric pyrazolidin-3-ones. Compound 167 eluted from the column
after its stereoisomer: IR (neat) 3500-3000 (br), 1681 cm-1; 1H NMR (300
MHz, CDCI3) S 5.65 (bs, 2H), 4.30 (dq, J = 6.5, 2.5, 1H), 3.7-3.4 (m, 2H), 3.4850
(s, 1H), 2.58-2.50 (m, 1H) 1.20 ( d, J= 6.5 Hz, 3H);13C NMR (75 MHz,
CDCI3) 8 177.3, 64.9, 49.6, 45.9, 21.3; MS (El)m/z (rel. intensity) 130
(M+,20), 112 (29), 85 (100), 69 (50); HRMS, m/z calcd. for C5H1oN202(M+):
130.0742. Found: 130.0741.
4-[(11-(Tert-Butyldimethylsilyloxy)ethy1]-1-(0-
nitrobenzyl)pyrazolidin-3-one (169). To a solution of 167 (1.57 g, 12.1
mmol) in dimethylformamide (30 mL) was added o-nitrobenzyl chloride
(2.07g, 12.1 mmol), triethylamine (1.68 mL, 12.1 mmol), and sodium iodide
(903 mg, 6.05 mmol). The reaction mixture was stirred under argon for 36 h at
room temperature, and the dimethylformamide was removed in vacuo.The
crude material was taken up in methylene chloride (20 mL) and washed with
water (2 x 20 mL), saturated sodium chloride (2 x 20 mL), dried over
anhydrous magnesium sulfate, and concentratedin vacua
The crude product (3.50 g) was diluted with dimethylformamide (75 mL)
and tert-butyldimethylsilyl chloride (2.00 g, 13.3 mmol) was added along with
imidazole (1.36 g, 19.9 mmol). The mixture was stirred under argon at room
temperature for 24 h and then partitioned between water (30 mL) and ether
(30 mL).The aqueous layer was washed with ether (2 x 30 mL) and the
organic layers combined, dried over anhydrous magnesium sulfate, and
concentratedin vacuo.Purification by column chromatography on silica gel
with 1:1 ethyl acetate-hexane as elutant afforded 169 (2.59 g, 56% based on
167) as a yellow solid: mp 138-141°C; IR (thin film) 2955, 2929, 1696, 1528,
836, 668 cm-1; 1H NMR (300 MHz, CDCI3) 8 7.96 (d, 1H), 7.61-7.58 (m, 2H),
7.51-7.45 (m, 1H), 6.67 (s, 1H), 4.35-4.31 (m, 1H), 4.21 (s, 2H), 3.54-3.52 (m,
1H), 3.39-3.33 (m, 1H), 2.77-2.70 (m, 1H), 1.17 (d, J = 6.3 Hz, 3H), 0.87 (s,
9H), 0.07 (s, 3H), 0.05 (s, 3H); 13C NMR (CDCI3) 8 174.1, 149.3, 133.2, 131,5,51
130.9, 128.9, 125.0, 66.4, 61.1, 53.4, 47.6, 25.7 (x3), 18.9, 17.9, -4.6, -4.9; MS
(CI) m/z (rel. intensity) 380 (M + 1,100), 364 (26), 322 (39), 248 (15), 159 (18),
120 (19), 75 (14); HRMS, m/z calcd. for C181-130N304Si (M + 1): 380.2006.
Found: 380.2006. Anal. Calcd. for Ci 8H29N304Si: C, 56.96, H, 7.71, N,
11.08. Found: C, 57.20, H, 7.80, N, 11.13.
2-[(2-(Trimethylsily0ethoxycarbonylj-1-(o-nitrobenzyl)-4-[(11-
(tert-butyldimethysilyloxy)ethyl]pyrazolidin-3-one(170). To a
solution of 169 (2.59 g, 6.82 mmol) and (trimethylsilyl)ethyl azidoformate
(0.40 g, 7.51 mmol) in dry tetrahydofuran (100 mL).was added slowly sodium
hydride (0.33g, 8.18 mmol, 60% in mineral oil) at 0°C.After all the sodium
hydride was added, the reaction was stirred for 30 min at 0°C and 2 h at room
temperature. The reaction mixture was partitioned between water (30 mL)
and ether (30 mL), and the aqueous layer was separated and washed with
ether (2 x 30 mL). The combined ether layers were dried over anhydrous
magnesium sulfate then concentrated in vacuo.Purification by column
chromatography on silica gel using 30% ethyl acetate-hexane as elutant
provided 170 (2.28 g, 64%) as a colorless solid: mp 85-88°C (ether-hexane);
IR (neat) 2955, 1788, 1734, 1528, 1347, 1288, 1252, 859, 838, 779 cm-1; 1H
NMR (400 MHz, CDCI3) 8 7.95-7.92 (m, 2H), 7.67-7.63 (m, 1H), 7.48-7.45 (m,
1H), 4.44-4.24 (m, 5H), 3.14 (dd, J = 11.9, 12.0 Hz, 1H), 3.00-2.97 (m, 1H),
1.13 (d, J = 6.5 Hz, 3H), 1.10-1.05 (m, 2H), 0.80 (s, 9H), 0.05 (s, 3H), 0.04 (s,
9H), 0.03 (s, 3H); 13C NMR (75 MHz, CDCI3) 8 172.0, 149.9. 149.1, 133.3,
131.9, 131.4, 128.6, 124.5, 65.7, 65.6, 56.9, 48.0 (x2), 25.7 (x3), 22.3, 17.8,
17.6, -1.6 (x3), -4.5, 5.2; MS (CI) m/z (rel. intensity) 524 (M + 1,13), 496 (100),
480 (57), 452 (56), 73 (38), 41 (49); HRMS, m/z calcd. for C24H42N3O6Si2 (M
+ 1): 524.2612. Found: 524.2612.52
3-[(11-Tert-Butyldimethylsilyloxy)ethy1]-1-[(2-
(trimethylsilyl)ethoxycarbonypamino]azetidin-2-one(171). A
sample of 170 (1.10 g, 2.09 mmol) in absolute ethanol (100 mL) was
degassed for 1 hr in a quartz photochemical immersion well. The solution
was irradiated through a pyrex filler with a 450-Watt Hanovia lamp for 2 h at
0°C. The filter was changed to Vycor, and the solutionwas irradiated for
another 5.5 h at 0°C. The resulting solution was concentrated in vacuo to
provide a dark brown oil.Purification by column chromatography on silica gel
using 30% ethyl acetate-hexane as elutant afforded 171 (0.49 g, 60%) as a
colorless oil: IR (neat) 3275, 2955, 2930, 1786, 1781, 1733, 1515, 1472, 1179,
1062, 1046, 836 cm-1; 1H NMR (300 MHz, CDCI3) S 6.66 (bs, 1H), 4.26.-4.17
(m, 3H), 3.63-3.61 (m, 1H), 3.53-3.51 (m, 1H), 3.11-3.08 (m, 1H), 1.23 (d,
6.1 Hz, 3H), 1.04-0.98 (m, 2H), 0.86 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H), 0.04 (s,
9 H); 13C NMR (75 MHz, CDCI3) 8 168.8, 154.9, 65.7, 64.9, 55.3, 47.3, 25.6
(x3), 22.8,17.9,17.7, -1.2 (x3),-4.3, -5.0; MS (CI) m/z (rel. intensity) 389 (M +
1,17), 361(78),345 (100), 331(22), 317 (69), 185 (26), 73 (66); HRMS, m/z
calcd. for Ci7H37N204Si2 (M + 1): 389.2292. Found: 389.2292.
1-Amino-3-[(11-tert-butyldimethylsilyloxy)ethyl]azetidin-2-
one (172). To a solution of 171 (160 mg, 0.41 mmol) in acetonitrile (5 mL)
was added 1.0 M tetra-n-butylammonium fluoride solution (0.41 mL, 0.41
mmol) in tetrahydrofuran. The mixture was heated at 45°C for 4.5 h and
concentratedinvacuo to provide an oil.Purification by column
chromatography on silica gel using 1:1 ethyl acetate-hexane as elutant
provided 172 (63.0 mg, 60%) as a clear oil: IR (neat) 3332 (br), 2959, 2932,
2858, 1760, 1468, 1369, 1137, 1106, 1078, 1018, 985, 838, 778 cm-1; 1H
NMR (300 MHz, CDCI3) 8 4.19-4.13 (m, 1H), 3.96 (s,2H), 3.47-3.44 (m, 1H),53
3.40-3.37 (m, 1H), 2.99-2.95 (m, 1H),1.18 (d, J= 6.2 Hz, 3H), 0.86 (s, 9H),
0.06 (s, 6H); 13C NMR (75 MHz, CDCI3) 6 168.7, 65.0, 54.6, 47.3, 25.7, 22.8,
17.9,-4.24, -5.05; MS (CI) m/z (rel. intensity) 245 (M + 1,51), 229 (69), 187
(85), 83 (30), 49 (40); HRMS, m/z calcd. for Cii H25N202 (M + 1): 245.1685.
Found: 245.1685.Anal. Calcd. for Ci 1H24N202Si: C, 54.06, H, 9.91, N,
11.47. Found: C, 53.89, H, 10.02, N, 11.26.
1-Amino-3-[(11-hydroxy)ethyl]azetidin-2-one(173). To a
solution of 172 (33.7 mg ,0.14 mmol) in acetonitrile (5 mL), was added 1.0 M
tetra-n-butylammonium fluoridesolution(0.15 mL, 0.15 mmol)in
tetrahydrofuran. The mixture was stirred under argon atmosphere for 24 h at
room temperature and concentrated in vacuo to provide an oil.Purification by
column chromatography on silica gel provided 173 (6.0 mg, 34%). The
purification of this compound was not trivial.Four silica columns were
performed using 10% methanol-methylene chloride twice, followed by 5%
methanol-methylene chloride the remaining times. The tri-n-butylamine by-
product appears to elute at the same rate (Rf = .15, 10% methanol-methylene
chloride) as the desired compound: IR (neat) 3329-3205 (br), 2969, 1744,
1138, 1091, 1011, 795 cm-1; 1H NMR (300 MHz, CDCI3 ) 6 4.23-4.14 (m, 1H),
4.07 (bs, 2H), 3.46-3.45 (m, 2H), 3.07-3.03 (m, 1H), 2.22 (bs, 1H), 1.27 (d, J=
6.5 Hz, 3 H); 13C NMR (75 MHz, CDCI3 ) 6 168.7, 64.8, 54.0, 47.7, 21.7; MS
(El) m/z (rel. intensity) 130 (M+,5), 112 (25), 85 (36), 69 (98), 55 (100), 45 (79);
HRMS, m/z calcd. for C5H10N202 (M+): 130.0742. Found: 130.0741.
1-Trifluoroacetamido-3-[(11-tert-butyldimethylsilyloxy)-
ethyl]azetidin-2-one (181). To a solution of 172 (31 mg, 0.13 mmol) in
dry pyridine (1 mL) containing N,N-(dimethylamino)pyridine (2 mg)was54
added trifluoroacetic anhydride (61.6 lit, 0.38 mmol) at 0°C. The reaction
mixture was warmed to room temperature and stirred for 6 h. The pyridine
was removed in vacuo. The residue was dissolved in water (5 mL), extracted
with chloroform (3 x 5 mL), and the combined organic dried over anhydrous
magnesium sulfate and concentrated in vacuo.Purification by column
chromatography on silica gel using 30% ethyl acetate-hexane as elutant
provided 181 (23.8 mg, 55%) as a yellow oil: IR (neat) 3210, 2958, 2859,
1783, 1742, 1209, 1164 cm-1; 1H NMR (300 MHz, CDCI3) 8 4.22 (quint., J =
5.7 Hz, 1H), 3.73-3.70 (m, 2H), 3.26-3.21 (m, 1H), 1.23 (d, J = 6.2 Hz, 3H), 0.87
(s, 9H), 0.08 (s, 3H); 0.06 (s, 3H).
3-Methyl-azetidin-2-one (183). To a solution of 16149 (33.7 mg,
0.33 mmol) in benzene (2 mL) was added N,N-diphenylnitrosamine63 (72.6
mg, 0.37 mmol). The mixture was heated at reflux for 3 h and concentrated in
vacuo to a dark brown oil.Purification by column chromatography on silica
gel using 1:1 ethyl acetate-hexane as elutant gave 183 (15.7 mg, 55%) as a
clear oil: IR (neat) 3259 (br), 2971, 2902, 1739, 1195 cm-1; 1H NMR (300 MHz,
CDCI3) 8 5.90 (bs, 1H), 3.43 (t, J = 5.3, 1H), 3.29-3.18 (m, 1H), 1.30 (d, J = 7.5
Hz, 3H); 13 C NMR (75 MHz, CDCI3), 8 172.5, 46.2, 43.4, 13.6; MS (CI) m/z
(rel. intensity) 86 (M + 1, 99); HRMS, m/z calcd. for C4H8NO (M + 1): 86.0606.
Found 86.0606.
4-Methyl-azetidin-2-one (184). To a solution of 16249 (70.0 mg,
0.692 mmol) in benzene (5 mL) was added N,N-diphenylnitrosamine (151 mg,
0.76 mmol). The mixture was heated at reflux for 2 h and concentrated in
vacuo to a dark brown oil.Purification by column chromatography on silica
gel using 1:1 ethyl acetate-hexane as elutant gave 184 (30.0 mg, 51%) as a55
clear oil: IR (neat) 3266 (br), 2968, 2931, 1737, 1416, 1378, 1194 cm-1; 1H
NMR (300 MHz, CDCI3) 8 6.30 (bs, 1H), 3.77-3.70 (m, 1H), 3.09-3.02 (m, 1H),
2.50 (dd, J = 11.0, 2.0 Hz, 1H), 1.32 (d, J= 6.1 Hz, 3H); 13C NMR (75 MHz,
CDCI3) 8 168.1, 44.9, 43.8, 21.2; MS (CI) m/z (rel. intensity) 86 ( M + 1, 95);
HRMS, m/z Calcd. for C4H8NO (M + 1): 86.0607. Found 86.0601.
cis-3,4-Dimethylazetidin-2-one(185)andtrans-3,4-
Dimethylazetidin-2-one (186). To a solution of 16349 (59.7 mg, 0.52
mmol) in benzene (5 mL) was added N,N-diphenylnitrosamine (114 mg, 0.56
mmol). The mixture was heated at reflux for 3 h and concentrated in vacuo to
a dark brown oil.Separation of the two diastereomers by column
chromatography on silica gel using 1:1 ethyl acetate-hexane as elutant
provided 185 (27.0 mg, 52%) and 186 (8.0 mg, 15%) for a total yield of (67%)
both as clear oils: (185): Rf 0.10 (1:1 ethyl acetate-hexane), IR (neat) 3258
(br), 2975, 2936, 1743, 1382, 1356, 1203 cm-1;1H NMR: (300 MHz, CDCI3) 8
6.25 (bs, 1H), 3.80 (quint, J = 6.0 Hz, 1H), 3.25-3.20 (m, 1H), 1.19 (d, J= 6.5
Hz, 3H), 1.13 (d, J= 7.6 Hz, 1H); 13C NMR (75 MHz, CDCI3) 8 172.3, 47.6,
47.4, 15.9, 8.7; MS (CI) m/z (rel. intensity) 100 (M + 1, 100); HRMS, m/z Calcd.
for C5H10N0 (M + 1): 100.0762. Found: 100.0763. (186): Rf 0.15 (1:1 ethyl
acetate-hexane) IR (neat) 3256 (br), 2968, 2931, 1745, 1381, 1354, 1192,
1061 cm -1; 1H NMR (300 MHz, CDCI3) 8 6.00 (bs, 1H), 3.36 (dq, J= 6.1 Hz,
2.0 Hz, 1H), 2.72 (dq, J= 5.8 Hz, 1.2 Hz, 1H), 1.32 (d, J= 6.1 Hz, 3H), 1.27 (d,
J= 7.5 Hz, 3H); 13C NMR (75 MHz, CDCI3) 6 171.5, 52.8, 52.5, 20.3, 12.7; MS
(CI) m/z (rel. intensity) 100 (M + 1, 39), 59 (100); HRMS, m/z calcd. for
C5H10N0 (M + 1): 100.0762. Found: 100.0763.56
Azetidin-2-one (187). To a solution of 16449 (15.1 mg. 0.18 mmol)
in benzene (2 mL) was added N,N-diphenylnitrosamine (38.2 mg, 0.19 mmol).
The mixture was heated at reflux for 2 h and concentrated in vacuo to a dark
brown oil.Purification by column chromatography on silica gel using 5%
methanol-chloroform as elutant gave 187 (7.5 mg, 61%) as a clear solid; mp
74°C; IR (neat) 3294 (br), 2984, 2917, 1717, 1382, 1281, 1197 cm-1; 1H NMR
(300 MHz, CDCI3) 8 5.73 (bs, 1H), 3.29 (t, J. 4.2 Hz, 2H), 3.02-3.00 (m, 2H);
13C NMR (75 MHz, CDCI3) 8 169.1, 38.3, 35.1; MS (CI) m/z (rel. intensity) 72
(M + 1, 100); HRMS, m/z calcd. for C3H6NO (M + 1): 72.0449.Found:
72.0449.
4-[(Ethoxycarbonyl)methyl]azetidin-2-one (188). To a solution
of 1 6 549 (7.0 mg, 0.04 mmol) in benzene (1mL) was added N,N-
diphenylnitrosamine (9.3 mg, 0.05 mmol). The mixture was heated at reflux
for 2.5 h and concentrated in vacuo to a dark brown oil.Purification by column
chromatography on silica gel using 1:1 ethyl acetate-hexane as elutant gave
4.5 mg of product. A second column on silica gel to remove minor impurities
using 1:1 ethyl acetate-hexane produced 188 (4.2 mg, 65%) as a clear oil: IR
(neat) 3274 (br), 2983, 1761, 1733, 1380, 1189 cm-1; 1H NMR (300 MHz,
CDCI3) 8 6.09 (bs, 1H), 4.14 (q, J. 7.2 Hz, 2H), 3.96-3.89 (m, 1H), 3.17-3.10
(m, 1H), 2.74-2.50 (m, 3H), 1.25 (t, J. 7.2 Hz); 13C NMR (75 MHz, CDCI3) S
171.0, 166.9, 60.9, 43.8, 43.4, 39.9, 14.2; MS (CI) m/z (rel. intensity) 158 (M +
1, 25), (116, 100); HRMS m/z calcd. for C7F112NO3 (M + 1): 158.0817. Found:
158.0817. Anal. Calcd. for C7H11NO3: C, 53.49, H, 7.05, N, 8.91. Found: C,
53.38, H, 6.94, N, 8.96.57
3-01-[(Tert-butyldimethylsilyloxy)ethyl]azetidin-2-one(189).
To a solution of 172 (20.7 mg, 0.09 mmol) in benzene (3 mL) was added N,N-
diphenylnitrosamine (19.0 mg, 0.09 mmol). The mixture was heated at reflux
for 2 h and concentrated in vacuo to a dark brown oil.Purification by column
chromatography on silica gel using 1:1 ethyl acetate-hexane as elutant gave
189 (13.3 mg, 68%) as a white solid: mp 55-58°C; IR (neat) 3190 (br), 2955,
2932, 1747, 1467, 1252, 1196, 1144, 1078, 1031, 839 cm-1; 1H NMR (300
MHz, CDCI3) 8 5.77 (bs, 1H), 4.22-4.15 (m, 1H), 3.26 (t, J. 5.1 Hz, 1H), 3.34-
3.31 (m, 1H) 3.22-3.17 (m, 1H), 1.16 (d, J. 6.1 Hz, 3H), 0.85 (s, 9H), 0.04 (s,
6H); 13C NMR (75 MHz, CDCI3) 8 169.5, 65.2, 59.3, 37.6, 25.7 (x3), 22.5, 27.9,
-4.3, -5.0; MS (CI) m/z (rel. intensity) 230 (M + 1, 60), 214 (50), 172 (60), 133
(40), 115 (20), 98 (20), 55 (100); HRMS, m/z calcd. for C11 H23NO2Si (M + 1):
230.1576. Found 230.1577.
3-[(1'-Hydroxy)ethyl]azetidin-2-one (190). To a solution of 189
(11.0 mg, 0.048 mmol) in acetonitrite (1 mL) was added an excess amount of
5% hydrofluoric acid in acetonitrile.The mixture was stirred at room
temperature for 3 h and concentrated in vacuo.Purification by column
chromatography on silica gel using 1:1 ethyl acetate-hexane as elutant gave
190 (3.50 mg, 64%) as a clear oil: IR (neat) 3346 (br), 2964, 1731, 1378,
1203, 1093, 898 cm-1; 1H NMR (300 MHz, CDCI3) 8 5.87 (bs, 1H), 4.25-4.15
(m, 1H), 3.37-3.31 (m, 2H), 3.30-3.26 (m, 1H), 2.17 (bs, 1H), 1.27 (d, J. 7.5
Hz, 3H); 13C NMR (75 MHz, CDCI3) 8 169.4, 64.9, 58.7, 38.0, 21.3; MS (CI)
m/z (rel. intensity) 116 (M + 1, 43), 59 (100); HRMS, m/z calcd. for C5Hi0NO2
(M + 1): 116.0713. Found: 116.0711.58
(2R,3R)-Ethyl -2-ally) -3-hydroxybutyrate (201). To a solution of
diisopropylamine (6.37 mL, 45.3 mmol) in dry tetrahydrofuran (50 mL) was
added n-butyllithium (28.3 mL, 45.3 mmol, 1.60 M in hexanes) at -78°C. The
mixture was warmed to 0°C for 30 min and recooled to -78°C for a further 30
min. (3R)-Hydroxybutyrate 200 (2.85 g, 21.6 mmol) was added dropwise
using a syringe. The mixture turned yellow and was stirred for 45 min at -70°C
before neat ally! bromide (4.66 mL, 53.9 mmol) was added via syringe. The
reaction was sealed under argon atmosphere and stirred for 16h at 5°C then
recooled to -50°C and quenched with acetic acid (2 mL) and ether (5 mL). The
reaction mixture was transfered to a separatory funnel filled with water (20 mL)
and ether (25 mL) where the layers separated. The ether layer was washed
with saturated sodium bicarbonate (6 mL), saturated sodium chloride (6 mL),
and the aqueous layer washed with ether (2 x 20 mL). The combined ether
layers were dried over anhydrous magnesium sulfate and concentrated in
vacuo. Purification by column chromatography on silica gel using 1:3.5 ethyl
acetate-hexane as elutant gave 201 (2.16 g, 58%) as a light yellow oil: [a]D
-9.50° (c = 1.50, CHCI3); IR (neat) 3675, 2973, 1733, 1610, 1181 cm-1; 1H
NMR (400 MHz, CDCI3) 8 5.79-5.72 (m, 1H), 5.08 (dd, J. 15.7 Hz, 1.3 Hz,
1H), 5.04 (dd, J. 10.2 Hz, 1.1 Hz, 1H), 4.17 (q, J. 7.5 Hz, 3H), 3.93 (quint., J
= 6.3 Hz, 1H), 2.62 (d, J. 7.4 Hz, 1H), 2.49-2.40 (m, 3H), 1.28 (t, J. 7.2 Hz,
2H), 1.23 (t, J = 6.2 Hz, 3H); 13C NMR (100 MHz, CDCI3) 6 174.6, 134.8,
117.1, 67.8, 60.6, 52.1, 33.6, 21.4, 14.3; MS (CI) m/z (rel. intensity) 173 (M + 1,
100); HRMS, m/z calcd. for C9F11703 (M + 1): 173.1178. Found: 173.1177.
(2R,3R)-Ethyl -2-ally) -3-tert-butyl dimethylsilyloxybutyrate
(202). To a solution of 201 (2.16 g, 12.6 mmol) in dry dimethylformamide
was added tert-butyldimethylsilyl chloride (2.65 g, 17.6 mmol) and imidazole59
(1.70 g, 25.2 mmol). The mixture was stirred at room temperature for 16 h
under argon atmosphere and quenched with water (10 mL) and ether (20 mL).
The aqueous layer was washed with ether (3 x 30 mL), and the combined
organic layers were dried over anhydrous magnesium sulfate then
concentrated in vacuo.Purification by column chromatography on silica gel
using 30% ethyl acetate-hexane as elutant gave 180 (3.50 g, 97%) as a clear
oil: [a]D -24.3° (c = 1.63, CHCI3); IR (neat) 3083, 2933, 1738, 1643, 1467,
1254, 1182, 1095 cm-1; 1H NMR (400 MHz, CDCI3) 8 5.73-5.67 (m, 1H), 5.02
(dd, J= 16.9 Hz, 1.4 Hz, 1H), 4.97 (dd, J = 10.4 Hz, 1.9 Hz, 1H), 4.08 (dq, J.
7.5 Hz, 1.1 Hz, 2H), 3.98 (quint., J= 6.1 Hz, 1H), 2.47-2.41 (m, 1H), 2.36-2.19
(m, 2H), 1.22 (t, J= 7.1 Hz, 3H), 1.14 (d, J= 6.5 Hz, 3H), 0.83 (s, 9H), 0.03 (s,
3H), 0.00 (s, 3H); 13C NMR (100 MHz, CDCI3) 8 173.7, 135.7, 116.4, 69.4,
60.1, 54.2, 32.4, 25.7 (x3), 21.2, 17.9, 14.3, -4.3, -5.1; MS (CI) m/z (rel.
intensity) 287 (M + 1, 100); HRMS, m/z calcd. for C15H31 03Si (M + 1):
287.2042. Found: 287.2041.
(2R,3R)-Ethy1-2-[3'-(hydroxy)propyl]-3-(tert-
butyldimethylsilyloxy)butyrate (203). To a solution of 1.0 M borane-
tetrahydrofuran complex (12.5 mL, 12.5 mmol) was added 2- methyl -2- butene
(2.73 mL, 25.75 mmol) and the reaction stirred for 1.5 h at -10°C (methanol-ice
bath).Alkene 202 (2.38g,8.31mmol) was added dropwisein
tetrahydrofuran (5 mL). The reaction was stirred for 1.5 h at 0°C. A mixture of
30% hydrogen peroxide (5 mL), 1M sodium hydroxide (5 mL), and water (2
mL) was added slowly at 0°C. The mixture turned white and was allowed to
stir for an addiltional 1.5 h at 0°C before extracting with ether (3 x 30 mL). The
combined ether layers were dried over anhydrous magnesium sulfate and
concentratedin vacuo.Purification by column chromatography on silica gel60
using 30% ethyl acetate-hexane as elutant gave 181 (1.82 g, 72%) as a clear
oil: [a]pIR (neat) 3436 (br), 2931, 1735, 1450, 1254, 1190, 1109, 1060, 834
cm-1; 1H NMR (400 MHz, CDCI3) 8 4.11 (dq, J= 7.3 Hz, 2.1 Hz, 2H), 3.98
(quint., J= 6.7 Hz, 1H), 3.62-3.59 (m, 2H), 2.40-2.34 (m, 1H), 1.62-1.45 (m,
4H), 1.37 (t, J= 5.5 Hz, 1H), 1.24 (t, J= 7.2 Hz, 3H), 1.13 (d, J= 6.0 Hz, 3H),
0.83 (s, 9H), 0.03 (s, 3H), 0.00 (s, 3H); 13C NMR (100 MHz, CDCI3) 8 174.6,
69.8, 62.5, 60.2, 54.3, 30.7, 25.7 (x3), 24.1, 21.2, 17.9, 14.2, -4.3, -5.2; MS (CI)
m/z (rel. intensity) 305 (M + 1, 100); HRMS, m/z calcd. for C15H3304Si (M + 1):
305.2148. Found: 305.2148.
(4R,5R)-4-Ethoxycarbony1-5-(tert-butyl dimethylsilyloxy)
hexanoic acid (204). To a solution of 203 (1.82 g, 5.98 mmol) in dry
dimethylformamide (50 mL) was added pyridinium dichromate. The reaction
was stirred for 48 h at room temperature then poured into water (50 mL). The
phases were separated and the aqueous layer was extracted with ether (4 x
50 mL). The combined ether extracts were dried over anhydrous magnesium
sulfate and concentrated in vacuo. Purification by column chromatography on
silica gel using 1:1 ethyl acetate-hexane as elutant provided 204 (1.25 g,
66%) as a light yellow oil: [a]D-5.3° (c = 1.81, CHCI3); IR (neat) 3400-2900 (br),
2956, 2934, 1734, 1714, 1254, 835 cm-1; 1H NMR (400 MHz, CDCI3) S (dq, J
= 7.3 Hz, 2.0 Hz, 2H), 4.03 (quint., J= 6.5 Hz, 1H), 2.47-2.27 (m, 3H), 1.86 (q, J
= 7.6 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H), 1.15 (d, J= 6.4 Hz, 3H), 0.85 (s, 9H),
0,04 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCI3) 8 178.9, 173.7, 69.5,
60.4, 53.3, 31.9, 25.7 (x3), 22.6, 20.9, 17.9, 14.2, -4.4, -5.2; MS (CI) m/z (rel.
intensity) 319 (M + 1, 100); HRMS, m/z calcd. for C15H3105Si (M + 1):
319.1941. Found: 319.1940. Anal. Calcd. for C15H3005Si: C, 56.57, H, 9.49,
Si, 8.82. Found: C, 56.73, H, 9.45.61
(6R,5R)- 5- Ethoxycarbonyl -6- methyl- pyran -2 -one (205). To a
solution of 204 (1.25 g, 3.92 mmol) in acetonitrile (5 mL) was added excess
5% hydrofluoric acid in acetonitrile and the reaction stirred for 1.5 h at room
temperature. Saturated ammonium chloride (5 mL) was added and a white
precipitate appeared as the phases separated.The aqueous layer was
extracted with ether (2 x 5 mL). The combined organic layers were washed
with saturated sodium bicarbonate (2 x 5 mL), dried over anhydrous
magnesium sulfate, and concentrated in vacuo. The crude material was used
directly for the next reaction.
Mukaiyama's salt69 (1.00 g, 3.92 mmol), and triethylamine (1.64 mL,
11.7 mmol) were stirred under argon atmosphere in acetonitrile (20 mL). The
crude material was added by syringe as a solution in acetonitrile (5 mL). The
reaction was stirred for 1.5 h at room temperature and the acetonitrile
concentrated in vacuo.Purification by column chromatography on silica gel
using 1:1 ethyl acetate-hexane as elutant provided 205 (545 mg, 75%) as a
clear oil: [a]D + 73.4° (c = 1.26, CHCI3); IR (neat) 2984, 1731, 1245, 1217,
1181, 1104, 1050, 1028 cm-1; 1H NMR (400 MHz, CDCI3) 54.73 -4.67 (m, 1H),
4.17 (dq, J. 6.7 Hz, 2.2 Hz, 2H), 2.89-2.85 (m, 1H), 2.77-2.69 (m, 1H), 2.56-
2.48 (m, 1H), 2.22-2.03 (m, 2H), 1.37 (d, J. 6.6 Hz, 3H), 1.25 (t, J. 6.8 Hz,
3H); 13C NMR (100 MHz, CDCI3) 6 170.9, 170.5, 75.4, 61.2, 42.2, 27.2, 19.9,
18.1, 14.1; MS (CI) m/z (rel. intensity) 187 (M + 1, 100); HRMS, m/z calcd. for
C9H1504 (M + 1): 187.0970. Found: 187.0970.
(6R)-5-Ethoxycarbony1-6-methy1-3-thiophenyl-pyran-2-one
(206). To a solution of 205 (530 mg, 2.85 mmol) in dry tetrahydrofuran (100
mL) was added lithium bis(trimethylsilyl) amide (4.26 mL, 4.26 mmol, 1 M
solution in tetrahydrofuran) dropwise by syringe at -70°C. The mixture was62
stirred for 45 min at -70°C.The reaction was quenched with saturated
ammonium chloride (20 mL), extracted with ether (3 x 5 mL), the combined
organic layers dried over anhydrous magnesium sulfate, and concentrated in
vacuo.Purification by column chromatography on silica gel using 30% ethyl
acetate-hexane as elutant provided 206 (606 mg, 72%) as a 1:1 mixture of
diastereomers: IR (neat) 2985, 1729, 1448, 1387, 1248, 1191, 747, 695 cm-1;
1H NMR (300 MHz, CDCI3) 8 7.58-7.50 (m, 4H), 7.36-7.28 (m, 6H), 4.77-4.70
(m, 2H), 4.17 (q, J. 7.4 Hz, 4H), 4.13-4.03 (m, 1H), 3.88 (dd, J. 8.3 Hz, 8.2
Hz, 1H), 3.01-2.92 (m, 2H), 2.65-2.56 (m, 1H), 2.48-2.41 (m, 1H), 2.28-2.10 (m,
2H), 1.36 (d, J. 6.6 Hz, 6H), 1.27-1.21 (m, 6H); 13C NMR (75 MHz, CDCI3) 6
170.8, 170.3, 169.4, 168.6, 134.0 (x2), 133.6 (x2), 132.1, 129.2 (x2), 129.1
(x2), 128.7 (x2), 128.5, 75.0, 74.6, 61.4 (x2), 46.0, 43.8, 43.3, 41.7, 28.5, 27.4,
18.5, 17.4, 14.1 (x2); MS (CI) m/z (rel. intensity) 295 (M + 1, 100); HRMS, m/z
calcd. for C15H1904S (M + 1): 295.1004. Found: 295.1003. Anal. Calcd. for
C15H1804S: C, 61.20, H, 6.16, S, 10.89. Found: C, 61.02, H, 5.98 S, 10.80.
(6R)-5-Ethoxycarbony1-6-methyl-4,5-dihydro-2H-pyran-2-one
(199). To a solution of 206 (597 mg, 2.03 mmol) in methylene chloride was
added 73% m-chloroperbenzoic acid at -78°C. The reaction was stirred for 30
min at -78°C, then the methylene chloride was removed in vacuo. The residue
was taken up in ether (10 mL), washed with saturated sodium bicarbonate (2 x
5 mL), sodium sulfite (1 x 5 mL), and saturated sodium chloride (1 x 5 mL).
The ether layer was dried over anhydrous magnesium sulfate and
concentrated in vacuo. The sulfoxide product was taken on to the next
reaction without purification.
A solution of the sulfoxide (630 mg, 2.03 mmol) in dry toluene (50 mL)
and methylene chloride (3 mL) was heated for 15 h at 70°C. The reaction was63
concentrated in vacuo.Purification by column chromatography on silica gel
using 1:1 ethyl acetate-hexane provided 199 (319 mg, 85%) as a light yellow
oil: [a]D -35.5° (c = 2.02, CHCI3); IR (neat) 2983, 2938, 1744, 1714, 1672,
1260, 1094, 1050, 1030, 801, 749 cm-1; 1H NMR (300 MHz, CDCI3) 8 6.95-
6.93 (m, 1H), 5.41-5.37 (m, 1H), 4.22 (dq, J= 7.2 Hz, 1.8 Hz, 2H), 3.27-3.20
(m, 2H), 1.49 (d, J= 6.7 Hz, 3H), 1.30 (t, J= 7.1 Hz, 3H); 13C NMR (75 MHz,
CDCI3) 8 167.6, 163.2, 132.0, 131.9, 75.7, 61.2, 30.0, 21.7, 14.0; MS (CI) m/z
(rel. intensity) 185 (M + 1, 100); HRMS, m/z calcd. for C9H1309 (M+ 1):
185.0814. Found: 185.0813.
3- Ethyl -3- phenylselenyl - pyran -2 -one(210).To a solution of
20974 (298 mg, 2.33 mmol) in dry tetrahydrofuran (8 mL) at -70°Cwas added
lithium bis(trimethylsilyl)amide (2.56 mL, 2.56 mmol, 1.0 M solution in
tetrahydrofuran).The mixture was stirred for 20 min at -70°C when
phenylselenyl chloride (490 mg, 2.56 mmol) in dry tetrahydrofuran (2 mL) was
added via canula. The reaction was stirred for 1 h at -70°C then quenched
with saturated ammonium chloride (5 mL) and extracted with ether (3 x 5 mL).
The combined organic extracts were dried over anhydrous magnesium sulfate
and concentrated in vacuo. Purification by column chromatography on silica
gel using 1:3 ethyl acetate-hexane as elutant provided 210 (477 mg, 72%) as
a clear oil: IR (neat) 2970, 2938, 1719, 1253, 1158, 1123, 744 cm-1; 1H NMR
(300 MHz, CDCI3) 8 7.60-7.55 (m, 2H), 7.45-7.36 (m, 1H), 7.34-7.27 (m, 2H),
4.58-4.50 (m, 1H), 4.32-4.25 (m, 1H), 2.24-1.65 (m, 6H), 0.92 (t, J= 7.0 Hz,
3H); 13C NMR (75 MHz, CDCI3) 8 171.1, 138.1 (x2), 129.7, 128.9 (x2), 126.9,
69.2, 50.7, 31.4, 30.4, 21.6, 9.4; MS (CI) m/z (rel. intensity) 285 (M + 1, 64),
255 (40), 99 (100); HRMS, m/z calcd. for C13H1702Se (M + 1): 285.0393.
Found: 285.0394.64
3- Ethyl -3,4- dihydro -2H- pyran -2 -one (211). To a solution of 210
(470 mg, 1.66 mmol) in methylene chloride (20 mL) at 0°C was added 30%
hydrogen peroxide (0.30 mL, 2.49 mmol) and water (1 mL). The mixture was
warmed to room temperature for 20 min then extracted with methylene
chloride (3 x 25 mL).The combined organic layers were dried over
anhydrous magnesium sulfate and concentratedin vacuo.Purification by
column chromatography on silica gel using 1:3 ethyl acetate-hexane as
elutant provided 211 (190 mg, 91%) as a clear oil: IR (neat) 2970, 2939,
1725, 1468, 1131, 1125, 980 cm-1; 1H NMR (300 MHz, CDCI3) 56.55 (dd, J.
5.4 Hz, 4.4 Hz, 1H), 4.31 (t, J. 6.1 Hz, 2H), 2.40-2.32 (m, 2H), 2.30-2.24 (m,
2H), 1.03 (t, J= 7.6 Hz, 3H); 13C NMR (75 MHz, CDCI3) 6 165.0, 137.7, 134.3,
66.3, 24.2, 23.8, 12.4; MS (CI) m/z (rel. intensity) 127 (M + 1, 100); HRMS, m/z
calcd. for C71-11102 (M + 1): 127.0759. Found: 127.0759.
cis -4- Ethyl- 5 -[2'- (hydroxy)ethyl]pyrazolidin -3 -one (212). To a
solution of 211 (1.01 g, 8.01 mmol) in 100% ethanol (75 mL) was added neat
hydrazine-monohydrate (1.17 mL, 24.0 mmol). The mixture was refluxed for
62 h and the ethanol was removed in vacuo.Purification by column
chromatography on silica gel using 5% methanol-chloroform, then 15%
methanol-chloroform produced 212 (621 mg, 49%) as a white solid, 213
(380 mg, 30%), and 214 (98.0 mg, 8%) as clear oils.(212): Rf 0.15 (15%
methanol-chloroform); mp 101-106°C; IR (neat) 3229 (br), 2963, 2938, 2878,
1679 cm-1; 1H NMR (300 MHz, CDCI3) 8 7.18 (s, 1H), 3.88-3.79 (m, 3H), 3.5
(s, 1H), 2.55 (q, J = 7.6 Hz, 1H), 1.81-1.68 (m, 3H), 1.53-1.50 (m, 1H), 1.41-
1.31 (m, 1H), 1.01 (t, J. 7.4 Hz, 3H); 13C NMR (75 MHz, CDCI3) 8178.9, 61.6,
61.5, 47.7, 28.4, 17.5, 12.3; MS (CI) m/z (rel. intensity) 159 (M + 1, 100);
HRMS, m/z calcd. for C7F115N202 ( M + 1): 159.1133. Found: 159.1133. Anal.65
Calcd. for C7F114N202: C, 53.15, H, 8.92, N, 17.71. Found: C, 53.16, H, 9.09,
N, 17.44.(213): Rf 0.12 (15% methanol-chloroform); IR (neat) 3282 (br),
2926, 2871, 1650, 1530, 1457, 1383, 1057 cm-1; 1H NMR (300 MHz, CDCI3) 8
7.15 (s, 1H), 3.75-3.51 (m, 2H), 2.08-1.95 (m,1H), 1.79-1.42 (m, 6H), 0.85 (t, J
= 7.0 Hz, 3H); 13C NMR (75 MHz, CDCI3) 8176.6, 62.6, 47.1, 30.3, 28.9, 25.9,
12.0. (214): Rf 0.20 (15% methanol-chloroform); IR (neat) 3286 (br), 2982,
2923, 1865, 1617, 1532, 1459, 1053 cm-1; 1H NMR (300 MHz, CDCI3) 8 5.56
(t, J = 6.5 Hz, 1H), 3.75 (t, J. 6.4 Hz, 2H), 2.40-2.26 (m, 4H), 1.58 (bs, 2H),
1.02 (t, J. 7.3 Hz, 3H);
cis-4-Ethy1-542'-(hydroxy)ethylHo-nitrobenzyppyrazolidin-
3-one (215).To a solution of 212 (125 mg, 0.791 mmol) in dry
dimethylformamide (10 mL) was added o-nitrobenzyl bromide and
triethylamine (0.132 mL, 0.949 mmol). The reaction was stirred for 96 h at
room temperature in the dark before removing the dimethylformamide in
vacuo.Purification by column chromatography on silica gel using 5%
methanol-chloroform as elutant provided 215 (91.4 mg, 40%) as a clear
colorless glass: IR (neat) 3341 (br), 3109, 3076, 2965, 2939, 2878, 1692,
1528 cm-1; 1H NMR (400 MHz, CDCI3) 8 7.91 (d, J. 7.9 Hz, 1H), 7.58 (t, J.
7.3 Hz, 1H), 7.49-7.45 (m, 2H), 7.00 (s, 1H), 4.48 (d, J. 12.9 Hz, 1H), 4.16 (d,
J. 12.8 Hz, 1H), 3.72-3.61 (m, 3H), 3.00-2.94 (m, 1H), 2.54 (bs, 1H), 1.85-1.74
(m, 1H), 1.56-1.53 (m, 2H), 1.35-1.23 (m, 1H), 1.00 (t, J = 7.5 Hz, 3H); 13C
NMR (75 MHz, CDCI3) 8 177.3, 149.6, 133.1, 132.1, 131.3, 129.1, 125.0, 65.2,
60.1, 59.4, 42.6, 29.6, 17.3, 12.3; MS (CI) m/z (rel. intensity) 294 (M + 1,11), 60
(100); HRMS, m/z calcd. for C14H2oN304 (M + 1): 294.1454.Found:
294.1454. Anal. Calcd. for C14H19N304: C, 57.33, H, 6.53, N, 14.33. Found:
C, 57.20, H, 6.52, N, 14.36.66
cis-4-Ethy1-5-[2ctert-Butyldimethylsilyloxy)ethyl]-(o-
nitrobenzyppyrazolidin-3-one (216).To a solution of 215 (77.0 mg,
0.263 mmol)indry methylene chloride(5 mL) was added N,N-
diisopropylethylamine (91.0 0.525 mmol) and tert-butyldimethylsilyl
trifluoromethanesulfonate.The mixture was stirred for 1h at 0°C then
quenched with water (1 mL) and extracted with methylene chloride (3 x 5 mL).
The combined methylene chloride layers were dried over anhydrous
magnesium sulfate and concentrated in vacuo.Purification by column
chromatography using 1:1 ethyl acetate-hexane as elutant provided 216
(61.0 mg, 57%) as a white solid: mp 119-124°C; IR (KBr) 3159, 3067, 2957,
2930, 2857, 1697, 1528 cm-1; 1H NMR (300 MHz, CDCI3) S 7.86 (dd, J. 7.9
Hz, 1.2 Hz, 1H), 7.59-7.41 (m, 3H), 6.6 (s, 1H), 4.37 (d, J. 13.4 Hz, 1H), 4.19
(d, J. 13.3 Hz, 1H), 3.65-3.50 (m, 3H), 2.99-2.91 (m, 1H), 1.82-1.75 (m, 1H),
1.57-1.23 (m, 3H), 0.99 (t, J. 7.3 Hz, 3H), 0.83 (s, 9H), 0.00 (s, 3H), -0.01 (s,
3H); 13C NMR (75 MHz, CDCI3) S 177.2, 149.8, 132.8, 131.8, 131.5, 128.9,
124.9, 63.6, 59.6, 59.5, 42.5, 30.9, 25.9 (x3), 18.2, 17.7, 12.2, -5.4 (x2); MS
(CI) m/z (rel. intensity) 408 (M + 1, 100); HRMS, m/z calcd. for C20H34N304Si
(M + 1): 408.2319. Found: 408.2316.Anal. Calcd. for C20H33N304Si: C,
58.94, H, 8.16, N, 10.31.Found: C, 58.02, H, 7.95, N, 10.38 (The total
transferable sample was only 0.39 mg. Carbon accuracy at this quantity is ±
0.6-0.8%).
cis-4-Ethy1-5-[(2ctert-butyldimethylsilyloxy)ethyl]-2-[2ctert-
butyldimethylsilyl)ethoxycarbony1]-1-(o-nitrobenzyl)pyrazolidin-3-
one (217).To a solution of 216 (110 mg, 0.270 mmol)indry
tetrahydrofuran (10 mL) was added 2- (trimethylsilyl) -ethyl azidoformate and
cooled to 0°C. Sodium hydride (13 mg, 0.324 mmol, 60% in mineral oil) was67
added slowly, then the reaction was stirred for 3 h at 0°C which turned dark
orange in color. The reaction was quenched with water (5 mL) and extracted
with ether (5 x 10 mL).The combined organic layers were dried over
anhydrous magnesium sulfate and concentratedin vacuo.Purification by
column chromatography using 15% ethyl acetate-hexane as elutant provided
217 (142 mg, 95%) as a clear glass: IR (neat) 2956, 2889, 2863, 1786, 1737,
1531, 1260, 1094, 843 cm-1; 1H NMR (400 MHz, CDCI3) 8 7.83 (dt, J. 7.7 Hz,
1.2 Hz, 2H), 7.56 (dt, J. 8.3 Hz, 1.1 Hz, 1H), 7.42 (dt, J. 7.3 Hz, 1.1 Hz, 1H),
4.56 (d, J. 12.9 Hz, 1H), 4.27-4.15 (m, 2H), 4.07 (d, J. 13.1 Hz, 1H), 3.60-
3.55 (m, 1H), 3.54-3.50 (m, 1H), 3.43-3.40 (m, 1H), 3.12-3.09 (m, 1H), 1.87-
1.75 (m, 1H), 1.48-1.41 (m, 1H), 1.35-1.24 (m, 2H), 1.04-0.99 (m, 2H), 0.98 (t, J
= 7.2 Hz, 3H), 0.74 (s, 9H), 0.01 (s, 9H), -0.08 (s, 3H), -0.13 (s, 3H); 13C NMR
(100 MHz, CDCI3) 8 173.9, 150.6, 149.9, 133.0, 132.7, 131.1, 129.8, 124.2,
65.5, 59.6, 59.1, 55.4, 44.8, 30.8, 25.8 (x3), 18.1 (x2), 17.5, 11.7, -1.6 (x3), -5.5
(x2); MS (CI) m/z (rel. intensity) 552 (M + 1,19), 524 (100), 508 (63), 480 (42),
466 (28); HRMS, m/z calcd. for C26H46N3O6Si2 (M + 1): 552.2925. Found:
552.2925.
cis-3-Ethy1-4-[(2ctert-butyldimethylsiloxy)ethyl]-112'-
(trimethylsilyl)ethoxycarbonypamino]azetidin-2-one(218). A
solution of 217 (160 mg, 0.290 mmol) in abslolute ethanol (100 mL) was
degassed with argon for 2 h in a photochemical immersion well. The solution
was irradiated for 1.5 h at 0°C through a pyrex filter with a 450-W Hanovia
medium-pressure photochemical lamp. The pyrex filter was then replaced by
a vycor filter and the solution irradiated for a further 1.5h at 0°C. The mixture
was concentrated in vacuo to a dark brown oil.Purification by column
chromatography on silica gel produced 218 (62.2 mg, 52%) as a pale yellow68
oil: IR (neat) 3264, 2954, 2894, 2863, 1777, 1732, 1249, 838 cm-1; 1H NMR
(400 MHz, CDCI3) 6 6.5 (s, 1H), 4.22 (dt, J. 7.4 Hz, 1.9 Hz, 2H), 4.04 (q, J.
6.3 Hz, 1H), 3.75-3.69 (m, 2H), 3.07-3.00 (m, 1H), 1.84 (q, J. 6.3 Hz, 1H), 1.08
(t, J. 7.4 Hz, 3H), 1.01 (t, J. 8.3 Hz, 2H), 0.90 (s, 9H), 0.06 (s, 6H), 0.04 (s,
9H); 13C NMR (100 MHz, CDCI3) 6 171.0, 155.2, 64.8, 60.7, 58.4, 51.5, 32.2,
25.9 (x3), 18.5, 18.3, 17.7, 12.5, -1.6 (x3), -5.4 (x2); MS (CI) m/z (rel. intensity)
417 (M + 1, 23), 389 (50), 133 (43), 51 (100); H-RMS, m/z calcd. for
C19H41 N204Si2 (M + 1): 417.2605. Found: 417.2606.
cis-1-Amino-3-ethyl-4-(2'(hydroxy)ethyl]azetidin-2-one
(219). To a solution of 218 (52.0 mg, 0.13 mmol) in acetonitrile (2 mL) was
added tetra-n-butylammonium fluoride (0.13 mL, 0.13 mmol, 1.0 M in
tetrahydrofuran).The mixture was stirred at room temperature for 4 h;
however, from thin layer chromatographic analysis, it was apparent that
cleavage of both silyl groups was occurring. A further equivalent of tetra-n-
butylammonium fluoride (0.13 mL, 0.13 mmol, 1.0 M in tetrahydrofuran) was
added and the reaction stirred for an additional 2 h at room temperature
before being concentrated in vacuo.Purification by column chromatography
using 5% methanol-chloroform provided 219 (19.8 mg, 51%) as a clear oil: IR
(neat) 3326 (br), 2961, 2928, 2880, 1740, 1048 cm-1; 1H NMR (300 MHz,
CDCI3) 8 4.20 (bs, 2H), 3.89-3.77 (m, 1H), 3.76-3.67 (m, 2H), 2.98-2.91 (m,
1H), 1.95-1.85 (m, 1H), 1.84-1.49 (m, 3H), 1.06 (t, J= 7.3 Hz, 3H); 13C NMR
(75 MHz, CDCI3), 6 170.9, 60.9, 60.8, 51.4, 32.8, 18.5, 12.6.
cis -3- Ethyl- 4 -(2'- (hydroxy)ethyl]azetidin -2 -one(220).To a
solution of 219 (6.0 mg, 0.038 mmol) in benzene (2 mL) was added N,N-
diphenylnitrosamine63 (11.3 mg, 0.057 mmol). The mixture was heated at69
reflux for 3 h and concentrated in vacuo to a dark brown oil.Purification by
column chromatography on silica gel twice using 5% methanol-chlorofom as
elutant provided 220 (4.1 mg, 76%) as a clear oil: IR (neat) 3288 (br), 2960,
2931, 2880, 1734, 1384, 1058 cm-1; 1H NMR (300 MHz, CDCI3) 8 6.2 (s, 1H),
3.86-3.70 (m, 3H), 3.10 (q, J = 7.3 Hz, 1H), 1.85-1.64 (m, 3H), 1.62- 1.50 (m,
1H), 1.04 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCI3) 8 171.7, 61.2, 54.9,
50.4, 33.0, 18.2, 12.6; MS (CI) m/z (rel. intensity) 144 (M + 1, 100); HRMS, m/z
calcd. for C7H14N20 (M + 1): 144.1025. Found: 144.1025.70
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Part II: Synthesis of a Subunit of the Immunosuppressant FK-506.
II-A. Introduction
The search for new metabolites from microorganisms for therapeutic
purposes continues to be a major theme of natural products research. FK-506
(1), a 23-membered macrolide, was isolated in 1987 from the soil fungus
Streptomyces tsukubaenis, and its structure was elucidated by chemical
degradation and X-ray crystallographic analysis.1FK-506 and the related
substance rapamycin (2), isolated in 1975 from Streptomyces hygroscopicus,2
share many structural features and have been found to possess powerful
immunosuppressant activity.Suppresion of the immune system to avoid
rejection is a valuable adjunct to surgery in organ transplant operations. FK-
506 has been used successfully in liver, kidney, and pancreas transplants with
no serious side effects3 and appears likely to replace cyclosporin A4 as the
drug of choice for this purpose.
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The mode of action of FK-506 involves inhibition of the adaptive immune
system.5Specifically, it forms a complex with the FK-506 binding proteins
which, through an undetermined mechanism,7 causes deactivation of T cells577
necessary for regulating antibodies and other white blood cells used by the host
to combat foreign antigens.Suppression of this immune mechanism is
necessary for reducing the rejection of tissue obtained from the transplant.
The exceptional biological activity of FK-506 has resulted in extensive
work directed toward the synthesis of this material.9 Two total syntheses10,11
have been reported along with two formal syntheses.12,13
The C20-C34 fragment 3 of FK-506 represents a critically important
portion of the molecule for which C20 is a logical synthetic disconnection point.
This fragment has been constructed using several different strategies as
outlined below.
3
Jones and co-workers at Merck applied Evans' aldol technology utilizing
a series of chiral condensations to build the desired fragment.10 Hydroxy
lactone 6, available in two steps from (±)-3-cyclohexenecarboxylic acid 5, was
converted to aldehyde 7 in four steps (Scheme 1). Condensation of 6 with 2-
lithio-2-triethylsily1 propanal t- butylimine14 gave aldehyde 8, the substrate for
the first aldol condensation.Treatment of 8 with the enol borinate of
oxazolidinone 915 afforded, after transamination and silylation, a 1:1 mixture of
diastereomers 10 and 11,which were readily separated.OHC
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Optically active amide 10 was reduced to aldehyde 12 which underwent
aldol condensation with the enol borinate of 1315 to give 14 in excellent yield79
(Scheme 2). Reductive dehalogenation followed by transamination, silylation,
and reduction provided aldehyde 15. A further condensation using oxazolidine
1615 gave the aldol product 17. Five additional steps were needed to construct
the desired aldehyde 18 used in the first total synthesis of FK-506.10
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The original plan devised by the Merck group involved an asymmetric
synthesis of hydroxy lactone 616 from bicyclic lactone 19, readily available from
(-)-quinic acid.17 Lactone 19 was converted to bis-thiocarbonyl lactone 20
which, on reduction with two equivalents of n-tributyltin hydride in the presence
of a,a'-azoisobutyronitrile (AIBN) gave 6 in moderate yield (Scheme 3). This81
strategy was later abandoned in favor of the scheme previously outlined due to
problems which arose with large scale synthesis of 6.
CICI-12CH2C1, A, (74%)
20
n-Bu3SnH (2 eq.),
AIBN, xylene, 140°C,
1h, (40%)
Scheme 3
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In a different approach, Schreiber and co-workers synthesized the C20-
C34 fragment utilizing a convergent strategy which entailed coupling at C26-
C27.11 This assembly was accomplished using optically active intermediates
21 and 22. The construction of 21 was completed utilizing lactone 24 (Scheme
4), available in six steps from the divinyl carbinol 23. Claisen rearrangement of
the silyl enol ether of 24, followed by transesterification, provided ester 25.
Regio- and stereoselective hydroboration followed by silylation afforded82
cyclohexane 26 which was homologated to alkyne 27 infour steps.
Hydrozirconation and bromination of 27 furnished the desired vinyl bromide 21.
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The synthesis of aldehyde 22 started with the conversion of 13-keto ester
28 into acetal 29 in four steps using an asymmetric reduction and a83
stereoselective alkylation (Scheme 5). The allyl group was cleverly protected
as a cyclic iodoether, and the p-methoxybenzylidene acetal was smoothly
converted to aldehyde 30.Chelation-controlled crotylation of 30 afforded
homoallylic alcohol 31 which was converted to 22 in two steps.
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The coupling of 21 with 22 proceeded via halogen metal exchange of 21
with t-butyl lithium, followed by subsequent addition to 22, to give predominantly
the desired adduct 32. A further three steps were needed to secure the C20-
C34 fragment 33 used in the total synthesis of FK-50610 (Scheme 6).
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Severalresearchgroupshaveusedopticallyactive3-
cyclohexenecarboxylic acid 5 as the starting material for a route to FK-85
506.12,18,19 Asymmetric Diels -Alder methodology was used to gain access to
the cyclohexene moiety.
Smith and co-workers showed that the chiral sultam 3420 and butadiene
underwent a Lewis acid-catalyzed Diels -Alder reaction which, after hydrolysis of
the chiral auxilliary, provided 5 in good yield with 93% enantiomeric excess
(Scheme 7).18 lodolactonization followed by elimination gave bicyclic lactone
35 which was converted to sulfone 36 in four steps. Regio- and stereoselective
hydroboration with subsequent silylation afforded 37. This was coupled with
aldehyde 38, available in six steps from crotyl alcohol, to give adduct 39. A
further four steps were needed for completion of the C24-C34 fragment 40.
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Danishefsky and co-workers synthesized 3-cyclohexenecarboxylic acid 5
by the same procedure as Smith's18 and converted it to sulfone 41 using again
a strategy similar to that of the Smith route. This intermediate was used in the
construction of fragment 42 to complete a formal synthesis of FK-506 (Scheme
8).12 Thus, sulfone 41 was coupled to aldehyde 43, and the resulting alcohol
44 was converted to ketone 45 in two steps.Treatment of 45 with87
methylmagnesium bromide provided an intermediate carbinol which was
dehydrated with Burgess' reagent to an inseparable (6:1.5:1) mixture of the
three possible olefin isomers, the major product being the desired in-chain E
isomer 46. The isomer mixture, after exchanging the silyl protecting group, was
converted by hydroboration-oxidation to their corresponding alcohols which
were separated to yield 47 as the major product.Oxidation of 47 to its
aldehyde and condensation with oxazolidinone 48 gave 42 after silylation and
removal of the chiral auxilliary.
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Corey and Huang also used an asymmetric Diels-Alder strategy for entry
into the C24-C35 fragment 49.19 A titanium-catalyzed Diels-Alder addition of
butadiene to chiral acrylate 50, followed by hydrolysis, gave 5 which was
converted to aldehyde 51 using a method analogous to that of Jones8 (Scheme
9). Diastereoselective aldol condensation of 51 with 52 afforded thioester 53 in
excellent yield. Protection of the resulting alcohol, followed by reduction, gave
aldehyde 49. The latter is a variant of the intermediate prepared by Jones.10OOH
PhS
1.
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Sih and Gu reported a formal synthesis of FK-506 which entailed
construction of the C20-C34 segment 55 via a coupling reaction of aldehyde 62
and ketone 6313 (Scheme 10). Enantioselective lipase hydrolysis of racemic 57
provided optically active 58, which was converted in several steps to a mixture
of diastereomers 59.Diastereoselective lipase hydrolysis of the cyclohexyl90
acetate of 59 gave 60 and the alcohol 61. Ester 60 was converted to the
desired aldehyde 62 via a five-step reaction sequence. Coupling of aldehyde
62 with 63, available in six steps from ethyl(3S)-hydroxybutyrate, afforded 64
and 65 in a ratio of 4:6, respectively. The desired isomer 64 was converted to
54 using a four-step procedure.
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A recent report by Rama Rao and co-workers showed that (-)-quinic acid
(66) could be used as a practical starting material for the C20-C34 segment of
FK-506.21 Treatment of 66 with benzaldehyde led to the formation of tricyclic
lactone 67 in good yield.22Deoxygenation of the tertiary alcohol via the
xanthate, followed by regioselective ring opening of the benzylidene acetal23
and a second reduction with n-tributyltin hydride, provided bicyclic lactone 68.92
Functional group manipulation led to ester 69 and then to the primary bromide
70 in a total of six steps (Scheme 11). The Grignard reagent derived from 70
was coupled to ketone 71 which was made using Evans' aldol methodology.15
This sequence afforded 72 after dehydration (Scheme 12).
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The foregoing studies clearly indicate that the C20-C34 segment of FK-
506 is a logical subunit to target for synthesis in the global plan. Access to this
fragment using the trisubstituted olefin at C27-C28 to link the smaller segments
has been a popular strategy.This has ledto the use of3-
cyclohexenecarboxylic acid 5 as a frequent starting materia1.113,12,18,19
Although the several routes to this portion of FK-506 share many features in
common, each synthetic pathway has shown innovative use of contemporary
methodology in the course of assembling this subunit.94
II-B. Results and Discussion
The goal of this work was to develop an efficient entry to the total
synthesis of the immunosuppressant FK-506 (1).This was envisioned by
subdividing the macrolide into fragments which could later be assembled in a
stepwise fashion. When planning the synthetic strategy, it was decided that the
disconnection at C19-C20 and at C1 of the lactone moiety were the logical
retrosynthetic choices. This resulted in the C20-C34 subunit being the initial
target of interest.
1
The synthetic plan was based on the use of a suitably functionalized
cyclohexane intermediate which would allow for systematic assembly of the
required side chain (Scheme 13).It was envisioned that construction of the
target molecule 73 would take place via a stereoselective aldol condensation of
the protected aldehyde 74.This aldehyde would be available from
homologation of aldehyde 75 which, in turn, could be synthesized from ester 76.
An appropriate starting material for the synthesis of 76 would be (-)-quinic acid
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The decision to use (-)-quinic acid (66) as the point of departure stems
from the fact that it contains the required absolute stereochemistry and
functionality needed for accessing the cyclohexane moiety of FK-506.(-)-
Quinic acid is a relatively inexpensive starting material, and even though two
unwanted hydroxyl groups must be removed, its use as a starting material is
economically attractive.
(-)-Quinic acid (66) underwent acid-catalyzed acetalization with
benzaldehyde and subsequent y-lactonization to afford tricyclic lactone 67 as a
1:1 mixture of diastereomers in excellent yield21, 22, 24 (Scheme 14). Although
this initial step parallels that of Rama Rao,21 our route immediately diverges
after this reaction.Instead of deoxygenation at this point, regioselective ring
opening of 67 with N-bromosuccinimide was used to provide bicyclic bromo
benzoate 78.23,24 This was converted smoothly to imidazolide 79 with
thiocarbonyl diimidazole.2596
An important transformation at this stage was the simultaneous reduction
of both the alkyl bromide and imidazolide moieties thereby improving the two-
step methodology employed by Rama Rao.21 Treatment of 79 with excess n-
tributyltin hydride and a,a'-azobisisobutyronitrile in refluxing toluene afforded
bicyclic lactone 68 in good yield.25
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Initial attempts to selectively cleave the lactone moiety in 68 were
unrewarding.Treatment of 68 with one equivalent of diisobutylaluminum
hydride in toluene at -78°C gave aldehyde 80 in a disappointing 12% yield
which could not be improved in spite of many attempts at optimization (Scheme
14).
A selective base-catalyzed transesterification was also attempted using
1% sodium hydroxide or potassium carbonate in methanol.In each case, no
selectivity was observed, diol 81 being isolated as the major product. This diol
could be relactonized in poor yield to hydroxylactone 6, a previous intermediate
in FK-506 synthesis10,19 (Scheme 15).
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A straightforward solution to this problem proved to be a quantitative
acid-catalyzed lactone opening of 68 which provided alcohol 82. Treatment of
82 with diazomethane in the presence of a catalytic amount of boron trifluoride
etherate afforded methyl ether 6926 (Schemel6). An attempt to simultaneously
cleave the benzoyl group and reduce the ester group of 69 with two or three
equivalents of diisobutylaluminum hydride (DIBAL-H) gave the desired
aldehyde 83 in only 26% yield.
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At this point, it was found advantageous to replace the benzoyl group
with a protecting group which could be used for the duration of the synthesis.
Treatment of 69 with sodium methoxide yielded alcohol 84 which, upon
protection with trimethylsilylethoxymethoxy (SEM) chloride,27 afforded silyl99
ether 7 6 (Scheme 17).Reduction of 76 with one equivalent of
diisobutylaluminum hydride afforded the corresponding aldehyde, which,
without purification, was converted exclusively to (E)-a,13-unsaturated ester 85
via Wittig olefination28 using (carboethoxyethylidene)triphenylphosphorane.
Evidence to support the (E)-olefin geometry came from analysis of the 13C
NMR spectrum of 85. The C27 methyl signal is strongly shielded by the cis-
cyclohexyl moiety and appears at 12.5 ppm. This observation correlates with a
report by Smith, in which it is stated that the C27 methyl group resonates at
11.0 ppm for a related compound. This methyl group appears at 13.7 ppm in
FK-506.18
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Straightforward reduction of 85 afforded allylic alcohol 86, which upon
treatment with Dess-Martin periodinane 87,29 gave a,(3- unsaturated aldehyde
75 (Scheme 18). Treatment of enal 75 with the (Z)-crotylboronate 88,30 derived
from its corresponding diethanolamine complex and (R,R)- diisopropyl tartrate,31
gave a 2.4 :1 mixture of homoallylic alcohols 89 and 90.
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The major product 89 was assigned the configuration shown based on
the accepted transition state for this reaction (Figure 2).32 The first step in the
proposed mechanism is complexation of the aldehyde with the boronate to form
a tetrahedral boron species. The chirality of this chelate is determined by the
antirelationship between the aldehyde oxygen and the proximal
carboisopropoxy moiety. This results in si-face addition by the crotyl group in a
chair-like transition state with the R group of the aldehyde in a pseudo-
equatorial position.
(1.:1
Me
Figure 2. Transition State for the Crotylborinate Reaction.
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Thealcohol8 9wasprotectedusingt-butyldimethylsilyl
trifluoromethanesulfonate33 to afford silyl ether 91 in excellent yield (Scheme
19).Selective oxidative cleavage34 of the terminal olefin of 91 was
accomplished using catalytic osmium tetroxide in the presence of sodium
metaperiodate which gave the desired aldehyde 74.
The alcohol 89 was also converted to ester 92 using (S)-pipecolinic acid
protected as its t-butoxycarbonyl derivative 9335 in the presence of
dicyclohexylcarbodiimide. The protected amino acid 93 was synthesized from
commerciallyavailable(S)-pipecolinicacid 94using2-tert-
butyloxycarbonyloxyimino-2-phenylacetonitrile 9536 (eq. 1).Attempts to102
oxidatively cleave 92 under the same conditions as used for 91 resulted in
decomposition of starting material with no evidence of product formation.
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With the key aldehyde 74 in hand, attention now focused on the
synthesis of the ketone 100 needed for the aldol reaction to give 73.The
ketone was synthesized in four steps from ethyl (R)-3-hydroxybutyrate (96) by
the route shown in Scheme 20. The dianion of 96 was alkylated with allyl103
bromide which provided ester 97.37 Reduction of 97 using lithium aluminum
hydride resulted in diol 98. Selective protection of the primary alcohol afforded
trityl ether 9938 which, upon treatment with Dess-Martin periodinane,29 gave
ketone 100 in excellent yield.
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Synthesis of the C20-C34 segment 73 of FK-506 was completed by aldol
condensation of ketone 100 with aldehyde 74 using kinetically controlled
conditions39 (Scheme 21). Treatment of the lithium enolate of 100, prepared
with lithium bis(trimethylsilyl)amide, with 74 at -78°C for three minutes gave
aldol adducts 73 and 101 in a 9:1 ratio as determined by 1H NMR analysis. The
selectivity observed in this condensation is a significant improvement on the 4:6
ratio of products reported for a similar aldol coupling by Sih.13
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The major product 73 is assigned 24(S) configuration based on a
transition state analysis of the coupling.Aldol reactions normally proceed
through a lithium-chelated, six-centered Zimmerman-Traxler transition state in
which the hydrogen atom of the aldehyde occupies a pseudoaxial position.40
The diastereofacial selectivity of attack at the aldehyde carbonyl can be
rationalized in this transition state using the Felkin-Anh principle,41 which
predicts for the case at hand that the incoming enolate approaches the si face105
of the aldehyde (Figure 3). This mode of attack would lead to (S) configuration
at the new stereogenic center produced in the aldol condensation.
R,,,,,,
H
H
n
OTr
Figure 3. Transition State for the Stereoselective Aldol Reaction.
In conclusion, the synthesis of the C20-C34 subunit 73 of FK-506 (1)
was accomplished in fifteen steps in an overall yield of 2.8%. Quinic acid (66)
as starting material allowed for quick access to the key intermediate aldehydes
74 and 75, and aldol condensation of 74 with the lithium enolate of 100 proved
to be a remarkably stereoselective and efficient method for elaborating the
desired fragment. The FK-506 segment 73 represents a strategic intermediate
that will allow for future studies directed at the construction of the entire
molecule.106
II-C. Experimental
General
General experimental techniques and instrumentation used in this work are
outlined in section IC.
(1R,3S,4S,5R)-4-Benzoyloxy-3-bromo-i-o-imidazothiocarbonyl-6-
oxabicyclo[3.2.1]octan-7-one (79). To a solution of 7823,24 (7.06 g, 20.7
mmol) in benzene (300 mL) was added 1,1'-thiocarbonyldiimidazole (4.05 g,
22.8 mmol). The mixture was heated at reflux for 44 h then concentrated in
vacuo.Purification by column chromatography on silica gel using 1:1 ethyl
acetate-hexane as elutant provided 79 (5.92 g, 63%) as a white solid: mp 147 -
148.5°C; [a]r) +68.0° (c = 1.10, CHCI3); IR (thin film) 1806, 1724, 1267, 1233,
1097, 1027, 714 cm-1; 1H NMR (300 MHz, CDCI3) 8 8.27 (s, 1H), 7.96 (dd, J
7.2 Hz, 1.3 Hz, 2H), 7.62-7.56 (m, 2H), 7.44 (t, J = 7.5 Hz, 2H), 6.97 (d, J = 1.3
Hz, 1H), 5.59 (t, J = 2.6 Hz, 1H), 5.09-5.06 (m, 1H), 4.55 (d, J = 7.3 Hz, 1H),
3.47 (dd, J = 14.9 Hz, 11.9 Hz, 2H), 3.07 (d, J = 11.9 Hz, 1H), 2.67 (d, J = 14.9
Hz, 1H); 13C NMR (75 MHz, CDCI3) 8179.0, 169.4, 164.2, 136.7, 134.0, 131.1,
129.7 (x2), 128.6 (x2), 128.1, 117.8, 81.8, 74.8, 71.3, 39.4, 37.9, 33.4; MS (CI)
m/z (rel. intensity) 453 (M + 1, 29), 451 (M + 1, 32), 69 (100); HRMS, m/z calcd.
for C18H1679BrN205S (M + 1): 450.9963. Found: 450.9963. Anal. Calcd. for
C18H1579BrN205S: C, 47.91, H, 3.35, N, 6.21, S, 7.10. Found: C, 47.86, H,
3.22, N, 6.04, S, 7.11.107
(1R,4R,5R)-4-Benzoyloxy-6-oxabicyclo[3.2.1]octan-7-one (68). To a
solution of tributyltin hydride (8.83 mL, 32.8 mmol) in refluxing toluene (200 mL)
was added dropwise a mixture of 79 (5.92 g,13.2 mmol) and a,a-
azobisisobutyronitrile ( 108 mg, 0.66 mmol) in toluene (100 mL) over a 10 min
period. The resulting mixture was stirred at reflux for 3 h, allowed to cool to
room temperature, and the toluene removed in vacuo. Ether (300 mL) was
added to the residue and washed with 2 M potassium fluoride (4 x 25 mL) and
the phases separated.The combined organic layers were dried over
anhydrous magnesium sulfate and concentrated in vacuo.Purification by
column chromatography on silica gel using 1:3 ethyl acetate-hexane as elutant
provided 68 (1.80 g, 56%) as a white solid: mp 135-139°C; [a]D -10.7° (c = 1.20,
CHCI3); IR (thin film) 3063, 3029, 2954, 1784, 1724, 1595, 1273, 1157, 1101,
757, 709 cm-1; 1H NMR (300 MHz, CDCI3) 8 8.02 (dd, J = 7.2, 1.6 Hz, 2H),
7.61-7.56 (m, 1H), 7.45 (dt, J= 7.8 Hz, 1.3 Hz, 2H), 5.35-5.31 (m, 1H), 4.91-
4.88 (m, 1H), 2.70-2.68 (m, 1H), 2.33 (d, J= 2.8 Hz, 2H), 2.13-2.05 (m, 2H),
1.93-1.87 (m, 2H); 13C NMR (75 MHz, CDCI3) 8 177.8, 165.3, 133.4,. 129.6
(x3), 128.5 (x2), 76.2, 67.6, 37.9, 32.1, 24.3, 23.0; MS (CI) m/z (rel. intensity)
247 (M + 1, 38), 59 (100); HRMS, m/z calcd. for C14H1504 (M + 1): 247.0970.
Found: 247.0970. Anal. Calcd. for C14H1404: C, 68.28, H, 5.73. Found: C,
68.28, H, 5.54.
(1R,3R,4R)-4-Benzoyloxy-3-hydroxy-cyclohexanal (80). To a solution
of68 (26.0 mg, 0.11mmol)indry toluene(2 mL) was added
diisobutylaluminum hydride (0.07 mL, 0.11 mmol, 1.5 M in toluene) at -78°C.
The reaction was stirred for 1h at -78°C then quenched with saturated
ammonium chloride (1 mL) and warmed to room temperature. The two phases
were partitioned and the aqueous layer was extracted with ethyl acetate (3 x 3108
mL). The combined organic extracts were dried over magnesium sulfate then
concentrated in vacuo.Purification by column chromatography on silica gel
using 1:1 ethyl acetate-hexane as elutant provided 80 (3.00 mg, 12%) as a
clear oil: IR (neat) 3474 (br), 2935, 1717, 1116, 713 cm-1; 1H NMR (300 MHz,
CDCI3) 8 9.65 (s, 1H), 8.05-8.03 (d, J = 7.2 Hz, 2H), 7.59-7.53 (t, J = 7.5Hz,
1H), 7.53-7.40 (t, J = 7.8Hz, 2H), 4.89-4.81 (m, 1H), 3.89-3.81 (m, 1H), 2.44-
2.22 (m, 3H ), 2.08-1.98 (m, 1H), 1.66-1.51 (m, 3H).
(1R,3R,4R)-1-Methoxycarbonylcyclohexan-3,4-diol (81). A solution of
68 (107 mg, 0.44 mmol) in 1% methanolic sodium hydroxide (5 mL) was stirred
for 1 h at room temperature. The pH was adjusted by the addition of 10 drops
of 1.5 M hydrochloric acid and the mixture extracted with ethyl acetate (5 x 20
mL). The combined organic extracts were dried over anhydrous magnesium
sulfate then concentrated in vacuo. Purification by column chromatography on
silica gel using 1:1 ethyl acetate-hexane as elutant provided 81 (60.2 mg, 80%)
as a white solid: mp 93-96°C; [a]D -12.2° (c = 1.20, CHCI3); IR (thin film) 3385,
2946, 2870, 1729, 1061 cm-1; 1H NMR (300 MHz, CDCI3) 8 3.68 (s, 3H), 3.45-
3.35 (m, 2H), 2.48-2.40 (m, 1H), 2.27-2.16 (m, 3H), 2.10-1.94 (m, 2H), 1.68-
1.25 (m, 3H); 13C NMR (75 MHz, CDCI3) 5 174.9, 74.9, 74.5, 51.8, 41.4, 34.9,
31.3, 26.9; MS (CI) m/z (rel. intensity) 175 (M + 1, 48), 157 (68), 125 (66), 59
(100); HRMS, m/z calcd. for C8H1504 (M + 1): 175.0970. Found: 175.0971.
(/R,4R,5R)-4-Hydroxy-6-oxabicyclo[3.2.1]octan-7-one (6).To a
solution of 81 (50.0 mg. 0.29 mmol) in benzene (1 mL) was added p-
toluenesulfonic acid monohydrate (27.4 mg, 0.14 mmol). The mixture was
refluxed for 8 h, allowed to cool, and the benzene was removed in vacuo.
Purification by column chromatography on silica gel using 1:1 ethyl acetate-109
hexane as elutant provided 6 (9.0 mg, 22%) as a clear glass: mp 159-162°C,
[Lit.19 m.p = 163.5-165°C]; [a]ci -18.8° (c = 1.69, CHCI3), [Lit19 [a]p -21.5° (c =
2.00, CHCI3)]; IR (thin film) 3421, 2961, 2903, 1751,1157, 971, 913 cm-1; 1H
NMR (300 mHz, CDCI3) 8 4.70-4.60 (m, 1H), 4.18 (s,1H), 2.39 (d, J = 14.5 Hz,
1H), 2.25-2.14 (m, 1H), 2.03-1.70 (m, 5H); 13C NMR (75mHz,CDCI3) 8 178.5,
78.9, 65.2, 38.4, 31.1, 27.3, 22.7; MS (CI) m/z (rel. intensity) 143 (M + 1, 100),
125 (72), 97 (28); HRMS, m/z calcd for C7E11103 (M + 1): 143.0708. Found:
143.0707.
(1R,3R,4R)-4-Benzoyloxy-1-methoxycarbonylcyclohexan-3-ol (82).
To a solution of 68 (15.0 mg, 0.06 mmol) in methanol (1 mL) was added
concentrated sulfuric acid (0.10 mL).The mixture was stirred at room
temperature for 15 min then quenched with saturated sodium bicarbonate (2
mL) and extracted with ethyl acetate (3 x 5 mL). The combined organic extracts
were dried over anhydrous magnesium sulfate then concentrated in vacuo to
obtain 82 (16.9 mg, 100%) as a white solid: mp 101-102°C; [a]) -35.8° (c =
1.30, CHCI3); IR (thin film) 3489, 3066, 2950, 2872, 1782, 1721cm-1; 1H NMR
(300 MHz, CDCI3) 8 8.04 (d, J = 7.4 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.45 (t, J
= 7.8 Hz, 2H), 4.91-4.83 (m, 1H), 3.83-3.75 (m, 1H), 3.70 (s, 3H), 2.53-2.19 (m,
4H), 2.07-2.03 (m, 1H), 1.72-1.45 (m, 3H); 13C NMR (75 MHz, CDCI3) 6 174.6,
166.7, 133.2, 130.0, 129.7 (x2), 128.4 (x2), 77.7, 71.8, 51.9, 40.9, 35.0, 28.5,
26.5; MS (CI) m/z (rel. intensity) 279 (M + 1, 100); HRMS, m/z calcd. for
C15H1905 (M + 1): 279.1233. Found: 279.1230.
(1R,3R,4R)-4-Benzoyloxy-3-methoxy-1-methoxycarbonyl-
cyclohexane (69). To compound 82 (15.7 mg, 0.06 mmol) in a solution of
diazomethane in ether (1 mL) was added boron trifluoride etherate (0.10 mL) at110
0°C. While stirring for 15 min at 0°C, the reaction decolorized yielding a white
precipitate and evolved nitrogen gas. The mixture was filtered to remove the
white solid, and the ether was removed in vacuo.Purification by column
chromatography on silica gel using 1:3 ethyl acetate-hexane as elutant
provided 69 (14.1 mg, 87%) as a clear oil: Lab -52.3° (c = 1.05, CHCI3); IR
(neat) 3065, 2948, 2874, 1786, 1724 cm-1; 1H NMR (300 MHz, CDCI3) 8 8.04
(dd, J = 7.1 Hz, 1.3 Hz, 2H), 7.58-7.52 (m, 1H), 7.43 (t, J = 7.2 Hz, 2H), 5.03-
4.95 (m, 1H), 3.70 (s, 3H), 3.62-3.33 (m, 1H), 3.40 (s, 3H), 2.47-2.37 (m, 2H),
2.26-2.21 (m, 1H), 2.04-1.98 (m, 1H), 1.69-1.45 (m, 3H); 13C NMR (75 MHz,
CDCI3) 6 174.5, 165.9, 132.8, 130.5, 129.6 (x2), 128.3 (x2), 80.2, 75.4, 57.6,
51.8, 40.8, 32.0, 28.8, 26.1; MS (CI) m/z (rel. intensity) 293 (M + 1, 100);
HRMS, m/z calcd. for C16H2105 (M + 1): 293.1389. Found: 239.1389. Anal.
Calcd. for C16H2005: C, 65.74, H, 6.90. Found: C, 65.88, H, 6.84.
(1R,3R,4R)-3-Methoxy-4-hydroxycyclohexanal (83). To a solution of
69 (33.3 mg, 0.11 mmol) in dry toluene (2 mL) was added diisobutylaluminum
hydride (0.23 mL, 0.34 mmol, 1.5 M in toluene) at -78°C. The reaction was
stirred for 1.5 h at -78°C then quenched with saturated ammonium chloride (1
mL) and warmed to room temperature. The two phases were partitioned, and
the aqueous layer was extracted with ethyl acetate (3 x 5 mL). The combined
extracts were dried over magnesium sulfate then concentratedin vacuo.
Purification by column chromatography on silica gel using 1:1 ethyl acetate-
hexane as elutant provided 83 (4.7 mg, 26%) as a clear oil: IR (neat) 3424 (br),
2936, 2869, 2830, 1721, 1094.cm-1; 1 H NMR (300 MHz, CDCI3) 8 9.64 (s, 1H),
3.46-3.40 (m, 1H), 3.43 (s, 3H), 3.07-3.01 (m, 1H), 2.68 (s, 1H), 2.45-2.39 (m,
1H), 2.35-2.29 (m, 1H ), 2.17-2.10 (m, 1H), 2.06-2.00 (m, 1H), 1.57-1.11 ( m,
3H).111
(1R,3R,4R)-3-Methoxy-1-methoxycarbonylcyclohexan-4-ol (84). To a
solution of 69 (323 mg, 1.11 mmol) in methanol ( 3 mL) was added sodium
methoxide (1.32 mL, 1.32 mmol, 1 M in methanol). The mixture was stirred at
room temperature for 1.5 h, and the methanol was removed in vacuo. The
residue was taken up in ether (10 mL) and acidified to pH = 3 with 1.5 M
hydrochloric acid (1.5 mL). The aqueous layer was extracted with ethyl acetate
(3 x 5 mL), and the combined organic extracts were dried over magnesium
sulfate then concentrated in vacuo. Purification by column chromatography on
silica gel using 1:1 ethyl acetate-hexane as elutant provided 84 (172 mg, 82%)
as a clear oil: [a]D -81.5° (c = 1.14, CHCI3); IR (neat) 3445 (br), 2946, 2873,
2833, 1732 cm-1; 1H NMR (400 MHz, CDCI3) 8 3.66 (s, 3H), 3.45-3.39 (m, 1H),
3.39 (s, 3H), 2.99-2.94 (m, 1H), 2.37-2.29 (m, 2H), 2.06-1.93 ( m, 2H), 1.48-
1.23 (m, 3H); 13C NMR (100 MHz, CDCI3) 8 174.8, 83.8, 73.0, 56.6, 51.7, 41.3,
30.8, 30.7, 26.6; MS (CI) m/z (rel. intensity) 189 (M + 1, 100), 157 (80), 139
(30); HRMS, m/z calcd. for C9H1704 (M + 1): 189.1127. Found: 189.1127.
Anal. Calcd. for C9H1604: C, 57.43, H, 8.57. Found: C, 57.44, H, 8.72.
(/R,3R,4R)-3-Methoxy-1-methoxycarbony1-4-
(trimethylsilylethoxy)methoxycyclohexane (76). To a solution of 84 (127
mg, 0.68 mmol) in chloroform (5 mL) was added diisopropylethylamine (0.50
mL, 2.70 mmol) along with trimethylsilylethoxymethoxy chloride (0.358 mL, 2.03
mmol). The mixture was refluxed 3 h, turning a dark orange color, allowed to
cool, and the chloroform removed in vacuo.Purification by silica gel column
chromatography using 1:3 ethyl acetate-hexane provided 76 (178 mg, 83%) as
a clear oil: [a]D -12.3° (c = 1.41, CHCI3); IR (neat) 2950, 2891, 1738 cm-1; 1H
NMR (300 MHz, CDCI3) 8 4.79 (s, 2H), 3.68-3.60 (m, 2H), 3.67 (s, 3H), 3.43-112
3.40 (m, 1H), 3.40 (s, 3H), 3.10-3.08 (m, 1H), 2.36-2.32 (m, 2H), 2.15-2.07 (m,
1H), 1.99-1.91 (m, 1H), 1.64-1.57 (m, 1H), 1.45-1.34 (m, 3H), 0.93 (dt, J = 9.6
Hz, J. 7.3 Hz, 2H); 13C NMR (75 MHz, CDCI3) 8 174.9, 94.4, 82.1, 78.4, 64.9,
57.2, 51.7, 40.9, 32.0, 30.0, 26.5, 18.0, -1.5 (x3); MS (CI) m/z (rel. intensity)
319 (M + 1, 64), 261 (100), 171 (99); HRMS, m/z calcd. for C15H3105Si (M +
1): 319.1941. Found: 319.1939. Anal. Calcd. for C15H3005Si: C, 56.57, H,
9.49, Si, 8.82. Found: C, 56.72, H, 9.60, Si, 8.36.
Ester 85. To a solution of 76 (94.5 mg, 0.30 mmol) in dry toluene (3 mL)
was added diisobutylaluminum hydride (0.22 mL, 0.33 mmol, 1.5 M in toluene).
The mixture was stirred for 1.5 h at -78°C, quenched with saturated ammonium
chloride (1 mL), and extracted with ethyl acetate (3 x 5 mL). The combined
organic extracts were dried over anhydrous magnesium sulfate then
concentrated in vacuo.
Asolutionofthecrudeproductfromaboveand
(carboethoxyethylidene)triphenylphosphorane (161 mg, 0.446 mmol) in dry
benzene (5 mL) was refluxed for 17 h. The benzene was removed in vacuo,
and the residue purified by column chromatography on silica gel, using 15%
ethyl acetate-hexane as elutant, to yield 85 (83.6 mg, 76%) as a clear oil: [a]D
-1.5° (c = 1.47, CHCI3); IR (neat) 2936, 2893, 2828, 1712 cm-1; 1H NMR (300
MHz, CDCI3) 8 6.52 (dd, J. 8.2 Hz, 1.2 Hz, 1H), 4.81 (s, 2H), 4.19 (q, J. 7.1
Hz, 2H), 3.73-3.61 (m, 2H), 3.48-3.41 (m, 1H), 3.41 (s, 3H), 3.17-3.09 (m, 1H),
2.43-2.30 (m, 1H), 2.24-2.02 (m, 2H), 1.85 (d, J = 1.4 Hz, 3H), 1.68-1.60 (m,
1H), 1.45-1.35 (m, 2H), 1.30 (t, J= 7.1 Hz, 3H), 1.26-1.10 (m, 2H), 1.00-0.852
(m, 3H), 0.02 (s, 9H); 13C NMR (75 MHz, CDCI3) 6 168.2, 144.7, 127.1, 94.4,
82.5, 78.9, 64.9, 60.6, 57.3, 35.7, 30.6, 29.8, 18.0, 14.3, 12.5, -1.4 (x3); MS (CI)
m/z (rel. intensity) 373 (M + 1, 27), 345 (53), 299 (73), 235 (100); HRMS, m/z113
calcd. for C19H3705Si (M + 1): 373.2410. Found: 373.2412. Anal. Calcd. for
C19H3605Si: C, 61.25, H, 9.74. Found: C, 61.46, H, 9.74.
Ally lic alcohol 86. To a solution of 85 (75.6 mg, 0.20 mmol) in dry ether
(4 mL) was added lithium aluminum hydride (23.1 mg, 0.61 mmol) at 0°C. The
reaction was warmed to room temperature over 1h, recooled to 0°C, then
quenched with water (1 mL) and 1.5 M hydrochloric acid (1 mL). The two
phases were partitioned, and the aqueous layer was extracted with ether (3 x 5
mL). The combined ether extracts were dried over anhydrous magnesium
sulfate then concentrated in vacuo. Purification by column chromatography on
silica gel using 1:1 ethyl acetate-hexane as elutant provided 86 (65.7 mg, 98%)
as a clear oil: [a]p +5.0° (c = 1.43, CHCI3); IR (neat) 3457 (br), 2933, 2893,
1052, 1030, 839 cm-1; 1H NMR (300 MHz, CDCI3) 8 5.21 (dd, J = 7.9 Hz, 1.0
Hz, 1H), 4.80 (s, 2H), 3.98 (d, J = 1.0 Hz, 2H), 3.70-3.60 (m, 2H), 3.43-3.37 (m,
1H), 3.40 (s, 3H), 3.15-3.07 (m, 1H), 2.75-2.25 (m, 1H), 2.10-2.00 (m, 2H), 1.68
(d, J = 1.2 Hz, 3H), 1.63-1.59 (m, 1H), 1.37-1.30 (m, 3H), 1.20-0.88 (m, 3H),
0.02 (s, 9H); 13C NMR (75 MHz, CDCI3) 8 134.0, 129.9, 94.4, 82.8, 79.2, 68.6,
64.8, 57.2, 36.4, 34.7, 30.9,30.8,18.0,13.8, -1.5 (x3); MS (CI) m/z (rel.
intensity) 331 (M + 1, 49),213(42),117 (100); HRMS, m/z calcd. for
C17H3504Si (M + 1): 331.2305.Found: 331.2305.Anal. Calcd. for
C17H3404Si: C, 61.77, H, 10.37. Found: C, 61.70, H, 10.25.
Aldehyde 75. To a soluton of 86 (270 mg, 0.08 mmol) in dry methylene
chloride was added the Dess-Martin periodinane 8729 (27.2 mg, 0.11 mmol)
and pyridine (13 p.1, 0.16 mmol) at room temperature.After 2 h, thin layer
chromatography indicated the presence of starting material, so a further
equivalent of 87 was added, and the mixture was stirred for an additional hour.114
The reaction was quenched by the addition of ether (3 mL) and 1 M sodium
hydroxide (1 mL). The two phases were partitioned, and the organic layer was
washed with water (2 mL), dried over anhydrous magnesium sulfate, and
concentratedin vacuo.Purification by column chromatography on silica gel
using 1:3 ethyl acetate-hexane provided 75 (22.1 mg, 83%) as a clear oil: [cc]p
+3.6° (c = 1.17, CHCI3); IR (neat) 2934, 2894, 1690, 1643, 1054, 837 cm-1; 1H
NMR (300 MHz, CDCI3) 8 9.37 (s, 1H), 6.23 (dd, J. 9.4 Hz, 1.4 Hz, 1H), 4.80
(s, 2H), 3.71-3.61 (m, 2H), 3.50-3.42 (m, 1H), 3.41 (s, 3H), _3.20-3.13 (m, 1H),
2.63-2.52 (m, 1H), 2.15-2.05 (m, 2H), 1.75 (d, J = 1.0 Hz, 3H), 1.75-1.68 (m,
1H), 1.48-1.11 (m, 3H), 1.00-0.89 (m, 2H), 0.01 (s, 9H); 13C NMR (75 MHz,
CDCI3) 8 195.3, 156.7, 138.1, 94.4, 82.2, 78.7, 64.9, 57.5, 35.9, 35.0, 30.5,
29.5, 18.0, 9.3, -1.5 (x3); MS (CI) m/z (rel. intensity) 329 (M + 1, 20), 117 (100);
HRMS, m/zcalcd. for C17H3304Si (M + 1): 329.2148. Found: 329.2148. Anal.
Calcd. for C17H3204Si: C, 62.15, H, 9.82, Si, 8.55. Found: C, 62.07, H, 9.91,
Si, 8.17.
Homoallylic alcohol 89. To a solution of 88 (122 mg, 0.41 mmol),
dervived from the (z)-crotylboronate diethanolamine complex and L-(R,R)-
diisopropyltartrate,31in dry toluene (1.5 mL) was added powdered 4 A
molecular sieves (150 mg) under argon atmosphere. The mixture was cooled
to -78°C and 75 (53.8 mg, 0.16 mmol) in dry toluene (1.5 mL) was added
dropwise over a 15 min period using a syringe pump. The reaction mixture was
stirred for 84 h at -78°C, then warmed to 0°C, 1 M sodium hydroxide (1 mL) was
added, and the mixture stirred for 20 min. The reaction was extracted with
ether (3 x 15 mL), and the combined ether extracts dried over anhydrous
magnesium sulfate then concentratedin vacuo.Purification by column
chromatography on silica gel using 15% ethyl acetate-hexane as elutant115
provided 89 (37.6 mg, 60%) and 90 (16.3 mg, 25%) both as clear oils: 89: Rf
0.08 (15% ethyl acetate-hexane), [a]D -3.3° (c = 3.60, CHCI3); IR (neat) 3462
(br), 2934, 2891, 1107, 1049, 1031, 854, 840 cm-1; 1H NMR (300 MHz, CDCI3)
8 5.77-5.61 (m, 1H), 5.17 (d, J = 8.9 Hz, 1H), 5.04-4.95 (m, 2H), 4.79 (s, 2H),
3.76 (d, J= 7.4 Hz, 1H), 3.69-3.58 (m, 2H), 3.44-3.35 (m, 1H), 3.39 (s, 3H),
3.14-3.04 (m, 1H), 2.35 (q, J = 7.0 Hz, 1H), 2.28-2.19 (m, 1H), 2.09-1.98 (m,
2H), 1.59 (d, J= 1.1 Hz, 3H), 1.40-1.22 (m, 1H), 1.15-0.86 (m, 5H), 0.99 (d, J=
6.9 Hz, 3H), 0.00 (s, 9H); 13C NMR (75 MHz, CDCI3) 8 141.0, 134.9, 131.1,
114.3, 94.4, 82.8, 80.5, 79.3, 64.8, 57.3, 41.1, 36.4, 34.7, 30.9, 30.7, 18.0,
14.7, 12.4, -1.4 (x3); MS (CI) m/z (rel. intensity) 385 (M + 1, 2.4), 205 (100).
Anal. Calcd. for C21H4004Si: C, 65.58, H, 10.48. Found: C, 65.80, H, 10.23.
90: Rf 0.10 (15% ethyl acetate-hexane) [a]D +5.6° (c = 1.40, CHCI3); 90 has
identical spectra [IR, 1H NMR, 13C NMR] to that of compound 89.
tert-Butyldimethylsilyl ether 91. To a solution of 89 (35.0 mg, 0.09
mmol) in methylene chloride (3 mL) was added tert-butyldimethylsilyl
trifluoromethanesulfonate (52.0 pt, 0.23 mmol) and diisopropylethylamine (48.0
lit, 0.27 mmol) under argon atmosphere. The mixture was stirred for 30 min at
0°C, and the methylene chloride was removed in vacuo. Purification by column
chromatography on silica gel using 5% ethyl acetate-hexane as elutant
provided 91 (43.6 mg, 96%) as a clear oil: [a]D -8.0° (c = 1.20, CHCI3) IR (neat)
2933, 2891, 2862, 1252, 1109, 1056, 838, 774 cm-1; 1H NMR (300 MHz,
CDCI3) 8 5.64-5.55 (m, 1H), 5.01 (d, J= 8.9 Hz, 1H), 4.85 (dddd, J= 17.8 Hz,
10.5 Hz, 2.0 Hz, 1.2 Hz, 2H), 4.78 (s, 2H), 3.68-3.56 (m, 3H), 3.43-3.35 (m,
1H), 3.40 (s, 3H), 3.13-3.04 (m, 1H), 2.27-2.18 (m, 2H), 2.04-1.96 (m, 2H), 1.53
(d, J= 1.0 Hz, 3H), 1.33-1.23 (m, 1H), 1.08-0.84 (m, 5H), 0.96 (d, J= 6.6 Hz,
3H), 0.85 (s, 9H), 0.00 (s, 9H), -0.01 (s, 3H), -0.07 (s, 3H); 13C NMR (75 MHz,116
CDCI3) 8 141.6,135.6, 130.9, 113.2,94.3,82.8,82.4,79.4, 64.8, 57.4, 42.4,
36.3, 34.7, 30.9,30.8, 25.9 (x3), 18.2,18.1,16.0,11.9,-1.4 (x3), -4.4, -5.0; MS
(CI) m/z (rel. intensity) 499 (M + 1, 22), 443 (100); HRMS, m/z calcd. for
C27H55O4Si2 (M + 1): 499.3639. Found: 499.3640.
Aldehyde74.To a solution of 91 (31.7 mg, 0.06 mmol) in
tetrahydrofuran (1 mL) and pH 7 phosphate buffer (1 mL, aqueous KH2PO4 and
Na2HPO4) was added osmium tetroxide (9.7 mL, 0.002 mmol, 4% in water)
along with one equivalent of sodium metaperiodate (15.0 mg, 0.06 mmol). The
reaction mxture was stirred for 4 h before an additional three equivalents of
sodium meta-periodate (40.7 mg, 0.18 mmol) were added. This mixture was
stirred for 20 h at room temperature, quenched with Na2S2O3 (1 mL), and
stirred an additional 20 min before being extracted with ether (3 x 5 mL). The
combined ether extracts were dried over magnesium sulfate then concentrated
in vacuo. Purification by column chromatography on silica gel using 30% ethyl
acetate-hexane as elutant provided 74 (19.8 mg, 62%), [alp -9.8° (c = 0.53,
CHCI3); IR (neat) 2931, 2893, 1727, 1460, 1054, 1034, 776 cm-1; 1H NMR (300
MHz, CDCI3) 8 9.62 (d, J. 2.0 Hz, 1H), 5.17 (d, J. 9.3 Hz, 1H), 4.78 (s, 2H),
4.21 (d, J. 5.8 Hz, 1H), 3.68-3.58 (m, 2H), 3.43-3.35 (m, 1H), 3.41 (s, 3H),
3.13-3.05 (m, 1H), 2.49-2.44 (m, 1H), 2.25-2.20 (m, 1H), 2.06-1.94 (m, 2H),
1.58-1.52 (m, 1H), 1.57 (d, J. 1.0 Hz, 3H), 1.33-1.23 (m, 1H), 1.08-0.87 (m,
4H), 0.99 (d, J. 6.9 Hz, 3H), 0.85 (s, 9H) 0.00 (s, 9H), -0.04 (s, 6H); 13C NMR
(75 MHz, CDCI3) 8 204.4, 134.0, 131.6,94.3,82.7,79.3, 77.2, 64.8, 57.5, 50.8,
36.3, 34.8, 30.8, 30.7, 25.7 (x3), 18.1,18.0,12.6,8.9, -1.4 (x3), -4.3, -5.2; MS
(CI) m/z (rel. intensity) 501 (M + 1, 1.3), 391 (100); HRMS, m/z calcd. for
C26H53O5Si2 (M + 1): 501.3432. Found: 501.3431.117
Ester 92. To a solution of 89 (23.7 mg, 0.06 mmol) in methylene
chloride (4 mL) was added dicyclohexylcarbodiimide (63.6 mg, 0.31 mmol) and
N,N-dimethylaminopyridine (15.0 mg, 0.12 mmol) under argon atmosphere.
The reaction mixture was stirred for 20 h at -15°C, quenched with saturated
sodium bicarbonate (3 mL), and allowed to stir for an additional 15 min at room
temperature. The organic layer was extracted with methylene chloride (3 x 10
mL), and the combined organic extracts were dried over magnesium sulfate
then concentratedin vacuo.Purification by column chromatography on silica
gel using 1:3 ethyl acetate-hexane as elutant provided 92 (26.4 mg, 72%) as a
clear oil: IR (neat) 2935, 2868, 1741, 1700, 1157, 1044 cm-1; 1H NMR (300
MHz, CDCI3, 333K) 8 5.66-5.57 (m, 1H), 5.25-5.18 (m, 1H), 5.03-4.80 (m,
2H),4.80-4.75 (m, 1H), 4.78 (s, 2H), 4.04-3.95 (m, 1H), 3.70-3.57 (m, 2H), 3.42-
3.34 (m, 1H), 3.39 (s, 3H), 3.11-3.03 (m, 1H), 3.00-2.90 (m, 1H), 2.49 (d, J.
6.9 Hz, 1H), 2.22-1.17 (m, 2H), 2.10-1.92 (m, 2H), 1.71-1.50 (m, 5H), 1.60 (s,
3H), 1.44 (s, 9H), 1.43-1.24 (m,5H),1.09-0.88 (m, 3H), 1.00 (d, J. 6.7 Hz, 2H),
0.01 (s, 9H); 13C NMR (75 MHz, CDCI3) 8 171.1, 155.8, 139.9, 133.3, 131.5,
131.4, 114.8, 94.6, 83.1, 82.9, 82.3, 79.8, 79.4, 64.9,40.2, 36.5, 35.1, 31.0,
30.7, 28.5 (x3), 26.9, 24.9, 24.7, 20.8, 18.2, 15.8, 13.1, -1.4 (x3).
N-(tert-ButoxycarbonyI)-L-piperidine-2-carboxylic acid (93). To a
solution of 94 (100 mg, 0.78 mmol) and 2-tert-butyloxycarbonyloxyimino-2-
phenylacetonitrile (BOC-ON) 95 (210 mg, 0.85 mmol) was added triethylamine
(0.16 mL, 1.16 mmol). The reaction mixture was stirred for 24 h at 25°C and
extracted with ether (3 x 5 mL) and the layers separated. The aqueous layer
was acidified with 1.5 M hydrochloric acid (2 mL) and extracted with ethyl
acetate (3 x 5 mL), and the combined organic extracts were dried over
magnesium sulfate then concentrated in vacuo to provide a white solid.118
Recrystallization using hexane (10 mL) provided 93 (114 mg, 64%) as a white
solid: mp 120-123°C [Lit42 mp 124°C]; [a]D -42.4° (c = 1.00, Me0H), [Lit42 [a]D
-45.1° (c = 1.0, Me0H)]; IR (thin film) 3431-2867 (br), 1738, 1699 cm-1; 1H
NMR (300 MHz, CDCI3) 8 4.95-4.62 (m, 1H), 4.10-3.88 (m, 1H), 3.00-2.80 (m,
1H), 2.23-2.15 (m, 1H), 1.75-1.60 (m, 2H), 1.43 (s, 9H), 1.50-1.22 (m, 3H); 13C
NMR (75 MHz, CDCI3, 323K) 8 177.2, 157.0, 79.9, 56.5, 42.2, 28.6 (x3), 27.3,
25.3, 21.1; MS (El) m/z (rel. intensity) 84 (100), 128 (60).
(2S,3S)-Ethyl-2-allyI-3-hydroxybutyrate (97). Hydroxy ester 9636 was
prepared in the same manner as described for thepreparation of its
enantiomer in part IC: 62% yield; colorless oil; [c(]D +7.8° (c = 0.55, CHCI3),
[Lit36 [a]D +14.5° (c = 0.37, CHCI3)].
(2S,3R)- 2- AIIyI -3- hydroxybutanol (98). To a solution of 97 (777 mg,
4.52 mmol) in dry ether (100mL) at 0°C was added lithium aluminum hydride
(514 mg, 13.6 mmol). The reaction mixture was allowed to warm to room
temperature over 2 h then recooled to 0°C before being quenched with water (5
mL) and hydrochloric acid (2 mL). The two phases were partitioned, and the
aqueous layer was washed with ethyl acetate (5 x 20 mL). The combined
organic extracts were dried over anhydrous magnesium sulfate then
concentrated in vacuo.Purification by column chromatography on silica gel
using 1:1 ethyl acetate-hexane as elutant provided 98 (402 mg, 68%) as a clear
oil: [a]D +3.2° (c = 2.57, CDCI3); IR (neat) 3353 (br), 3078, 2974, 2925, 2896,
1038, 912 cm-1; 1H NMR (300 MHz, CDCI3) 8 5.86-5.74 (m, 1H), 5.11-5.01 (m,
2H), 3.94-3.86 (m, 2H), 3.66 (dd, J = 6.2 Hz, 6.3 Hz, 1H), 2.57 (s, 2H), 2.25-
2.05 (m, 2H), 1.59-1.53 (m, 1H), 1.27 (d, J= 6.2 Hz, 3H); 13C NMR (75 MHz,
CDCI3) 8 136.4, 116.6, 71.4, 64.2, 45.9, 33.2, 22.0; MS (CI) m/z (rel. intensity)119
131 (M + 1, 44), 113 (43); HRMS, m/z calcd. for C17H1502 (M + 1): 131.1072.
Found: 131.1072.
(2S,3F1)-2-Ally1-3-hydroxy-[1-(triphenyl)methyoxy]butane (99). To a
solution of 98 (208 mg, 1.60 mmol) in dry methylene chloride (20 mL) was
added triphenylmethyl chloride (468 mg, 1.68 mmol) and triethylamine (0.25
mL, 1.76 mmol). The reaction mixture was stirred at room temperature for 24 h
then concentrated in vacuo. Purification by column chromatography on silica
gel using 15% ethyl acetate-hexane as elutant provided 99 (504 mg, 84%) as a
clear oil: [cc]D +4.9° (c = 1.33. CHCI3); IR (neat) 3438 (br), 3064, 2973, 2925,
2890, 1447, 1062, 703 cm-1; 1H NMR (300 MHz, CDCI3) 8 7.44-7.40 (m,6H),
7.32-7.20 (m, 9H), 5.70-5.558 (m, 1H), 4.96 (ddd, J = 17.1 Hz, 10.5 Hz, 1.2 Hz,
2H), 3.80 (q, J= 6.1 Hz, 1H), 3.33 (dd, J= 9.5 Hz, 3.8 Hz, 1H), 3.20 (dd, J. 9.5
Hz, 6.0 Hz, 1H), 2.87 (d, J= 4.8 Hz, 1H), 2.30-2.08 (m, 2H), 1.66-1.60 (m, 1H),
1.06 (d, J = 6.4 Hz, 3H); 13C NMR (75 MHz, CDCI3) 8 143.7 (x3), 136.6, 128.6
(x6), 127.9 (x6), 127.1 (x3), 116.4, 84.8, 70.1, 64.2, 45.1, 33.2, 21.0; MS (CI)
m/z (rel. intensity) 243 (100), 131 (M + 1-C19H15, 8.7).
(3R)-3-Ally1-[4-(triphenyOmethyoxy]butan-2-one (100). To a solution
of 99 (483 mg, 1.29 mmol) in dry methylene chloride (20 mL) was added the
Dess-Martin perodinane29 (658 mg, 2.58 mmol) and pyridine (0.209 mL, 2.58
mmol). The reaction mixture was stirred at room temperature for 3 h then
concentrated in vacuo.Purification by column chromatography on silica gel
using 15% ethyl acetate-hexane provided 100 (456 mg, 95%) as a white solid:
mp 40-44°C; [a]D -14.5°C (c = 2.03,CHCI3); IR (thin film) 3064, 3028, 2927,
1714, 1167, 704 cm-1; 1H NMR (300 MHz, CDCI3) 8 7.39-7.35 (m, 6H), 7.30-
7.18 (m, 9H), 5.64-5.52 (m, 1H), 4.98-4.91 (m, 2H), 3.32-3.22 (m, 2H), 2.76 (q,120
J = 6.4 Hz, 1H), 2.38-2.28 (m, 1H), 2.20-2.12 (m, 1H), 2.09 (s, 3H); 13C NMR
(75 MHz, CDCI3) 8 210.3, 143.7 (x3), 135.1, 128.6 (x6), 127.8 (x6), 127.0 (x3),
116.9, 86.7, 63.9, 52.8, 32.5, 29.8; neg. FABMS, m/z (rel. intensity) 369 [(M-
1)-, 16], 243 (20). Anal. Calcd. for C26H2602: C, 84.29, H, 7.07. Found: C,
84.40, H, 6.92.
Aldo! adduct (73). To a solution of 100 (12.3 mg, 0.04 mmol) in dry
tetrahydrofuran (.5 mL) was added lithium bis(trimethylsilyl)amide (35 lit, 0.04
mmol, 1.0 M in THF) at -78°C, and the mixture was stirred for 30 min. Aldehyde
74 (11.1 mg, 0.02 mmol) was added via a canula as a solutionin
tetrahydrofuran (0.5 mL).The reaction was immediately quenched with
saturated ammonium chloride (0.3 mL) after 3 min, warmed to room
temperature, dried over magnesium sulfate, and concentrated in vacuo.
Purification by column chromatography on silica gel using 15% ethyl acetate-
hexane as elutant provided a 9:1 mixture of 73 and 101 (12.3 mg, 62%) as a
clear oil: IR (neat) 3464 (br), 2934, 2891, 1706, 1450, 1033, 839 cm-1; 1H NMR
(300 MHz, CDCI3) 8 7.39-7.32 (m, 5H), 7.30-7.18 (m, 10H), 5.62-5.53 (m, 1H),
5.10 (d, J = 9.0 Hz, 1H), 4.97-4.90 (m, 2H), 4.79 (s, 2H), 4.07 (d, J= 4.2, 1H),
3.84-3.75 (m, 1H), 3.70-3.58 (m, 2H), 3.42-3.31 (m, 1H), 3.41 (s, 3H), 3.28-3.20
(m, 3H), 3.15-3.06 (m, 1H), 2.77-2.73 (m, 1H), 2.54-2.50 (m, 2H), 2.35-1.95 (m,
4H), 1.63-1.51 (m, 1H), 1.55 (s, 3H), 1.33-1.24 (m, 2H), 1.10-0.85 (m, 5H), 0.87
(s, 9H), 0.67 (d, J= 6.8 Hz, 3H), 0.01 (s, 3H), 0.00 (s, 9H), -0.07 (s, 3H); 13C
NMR (75 MHz, CDCI3) 8 213.9, 143.6, 135.2, 135.0 (x3), 130.1,128 6(x6),
127.9 (x6),127.1 (x3),117.1, 94.4, 86.9, 82.9, 79.4, 77.2,68.3,64.8,64.0,
57.6, 52.7,46.4, 41.6,36.6, 34.8, 32.4, 30.9, 30.8, 25.9 (x3),18.2,18.0,13.3,
9.6, -1.4 (x3), -4.4, -5.1; neg. FABMS, m/z (rel. intensity) 869 [(M- 1)-, 1.4], 243
(23), 131 (100).121
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